Treatment of solid tumors

By administering anti-FGFR2b antibodies, such as bematostuzumab, to patients, specific dosage regimens inhibit FGFR2b signaling, addressing the limited efficacy of existing therapies against FGFR2b-overexpressing solid tumors and achieving more efficient tumor suppression.

CN118974099APending Publication Date: 2024-11-15AMGEN INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380030698.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-03-24
Filing Date
2023-04-06
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing treatments for solid tumors have limited efficacy against tumors that overexpress FGFR2b, especially after multiple lines of therapy, necessitating a more effective targeted therapy.

Method used

Anti-FGFR2b antibody monotherapy, including administering anti-FGFR2b antibodies such as bematostuzumab to patients, inhibits FGFR2b signaling through a specific dosage regimen, blocks its binding to ligands, and inhibits tumor growth.

Benefits of technology

It significantly inhibited the growth of solid tumors overexpressing FGFR2b, especially after multiple lines of therapy, providing a more effective treatment option and improving patient treatment response and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118974099A_ABST
    Figure CN118974099A_ABST
Patent Text Reader

Abstract

Methods of treating solid tumors such as squamous cancer (such as head and neck squamous cell carcinoma), ER-PR-HER2 / neu-("triple negative") breast cancer, intrahepatic cholangiocarcinoma, lung adenocarcinoma, and gynecological malignancies in a subject are described. The methods can comprise administering to the subject an anti-FGFR2b antibody.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The embodiments herein relate to the use of antibodies against fibroblast growth factor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also referred to as FGFR2b), in the treatment of solid tumors, such as squamous carcinomas (such as head and neck squamous cell carcinoma), "triple negative" breast cancer, intrahepatic bile duct carcinoma, lung adenocarcinoma, and gynecological malignancies.

[0002] Incorporation by Reference of Electronically Submitted Materials

[0003] Incorporated herein by reference in its entirety is the Nucleotide / Amino Acid Sequence Listing filed concurrently herewith and identified as follows: a 13,839-byte XML document named "10131-WO01-SEC.xml", created on March 27, 2023.

[0004] CROSS-REFERENCE TO RELATED APPLICATIONS

[0005] This application claims the benefit of the following U.S. provisional applications: U.S. provisional application No. 63 / 328,789 filed on April 8, 2022; U.S. provisional application No. 63 / 377,266 filed on September 27, 2022; and U.S. provisional application No. 63 / 492,047 filed on March 24, 2023, the disclosures of which are incorporated herein by reference. Background Art

[0006] Fibroblast growth factor receptor 2b (FGFR2b) is overexpressed in a portion of gastric / gastroesophageal junction (GC / GEJ) cancers and is a target for novel therapies that may improve treatment outcomes. Fibroblast growth factor (FGF) family members bind to four known tyrosine kinase receptors, i.e., fibroblast growth factor receptors 1-4 (FGFR1 4) and isotypes thereof, and various FGFs bind to different FGFRs to varying degrees (Zhang et al., J.Biol.Chem. [Journal of Biological Chemistry] 281:15694,2006). The protein sequence of human FGFR2 is provided in, for example, GenBank locus AF487553. Each FGFR is composed of an extracellular domain (ECD) comprising three immunoglobulin (Ig)-like domains (D1, D2, and D3), a single transmembrane helix, and an intracellular catalytic kinase domain (Mohammadi et al., Cytokine Growth Factor Revs [Cytokine and Growth Factor Review], 16:107,2005). FGF binds to the receptor primarily through regions in D2 and D3 of the receptor. There is a stretch of consecutive acidic amino acids in the linker between D1 and D2, called the "acid box" (AB). The region containing D1 and AB is thought to be involved in the autoinhibition of the receptor, which is relieved by binding to the ligand.

[0007] The characteristic of FGFR is that its mRNA undergoes multiple alternative splicing, thereby producing a variety of isoforms (Ornitz et al., J. Biol. Chem. [Journal of Biological Chemistry] 271: 15292, 1996; also see Swiss-Prot P21802 and isoforms P21802-1 to -20 for the sequences of FGFR2 and its isoforms). It should be noted that there are forms containing all three Ig domains (α isoforms) or only two Ig domains D2 and D3 domains without D1 (β isoforms). In FGFR1, FGFR2 and FGFR3, all forms contain the first half of D3 (denoted as IIIa), but two alternative exons can be used for the second half of D3, thereby producing IIIb and IIIc forms. For FGFR2, these forms are respectively expressed as FGFR2-IIIb and FGFR2-IIIc (or respectively expressed as only FGFR2b and FGFR2c); the corresponding β forms are expressed as FGFR2 (β) IIIb and FGFR2 (β) IIIc. The FGFR2-IIIb form of FGFR2 (also expressed as K-sam-II) is a high affinity receptor for FGF1 and KGF family members (FGF7, FGF10 and FGF22), while FGFR2-IIIc (also expressed as K-sam-I) is well combined with FGF1 and FGF2 but not with KGF family members (Miki et al., Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States] 89: 246, 1992). In fact, FGFR2-IIIb is the only receptor for KGF family members (Ornitz et al., supra), so it is also called KGFR.

[0008] FGFR and its isoforms are differentially expressed in various tissues. FGFR2-IIIb (and the IIIb form of FGFR1 and FGFR3) is expressed in epithelial tissue, while FGFR2-IIIc is expressed in interstitial tissue (Duan et al., J.Biol.Chem. [Journal of Biological Chemistry] 267:16076,1992; Ornitz et al., 1996, ibid). Some FGF ligands of these receptors have opposite expression patterns. Therefore, KGF subfamily members (including FGF7 (KGF), FGF10 and FGF22) are only combined with FGFR2-IIIb (Zhang et al., ibid) and expressed in interstitial tissue, so it may be the paracrine effector of epithelial cells (Ornitz et al., ibid). In contrast, FGF4 subfamily member FGF4-6 is combined with FGFR2-IIIc and expressed in epithelial and interstitial lineages, so it may have autocrine or paracrine function. Due to the expression pattern of FGFR2 isoforms and their ligands, FGFR2 plays a role in epithelial-mesenchymal interactions (Finch et al., Dev. Dyn. 203:223, 1995), and knockout of FGFR2-IIIb in mice results in severe embryonic defects and lethality (De Moerlooze et al., Development 127:483, 2000).

[0009] In addition to gastric cancer, other epithelial malignancies have been reported to overexpress FGFR2 at the DNA or protein level, including head and neck squamous cell carcinoma (Brands et al., 2017), esophageal cancer (Kato et al., 2013), colorectal cancer (Li et al., 2019), intrahepatic bile duct carcinoma (Churi et al., 2014), pancreatic cancer (Kang et al., 2019), breast cancer (Reinjtes et al., 2013), ovarian cancer (Tyulyandina et al., 2018), cervical cancer (Sun et al., 2019), endometrial cancer (Gatius et al., 2011; Dutt et al., 2008) and other cancers (Wu et al., 2013). Treatment of such malignancies usually involves the use of multiple modalities, such as surgery, systemic anticancer therapy (SACT) and radiation therapy, either alone or in combination or sequentially. For some types of solid cancers, effective monotherapy is still needed. Summary of the invention

[0010] The present disclosure provides a method of treating a solid tumor in a subject, the method comprising administering to the subject an anti-FGFR2b antibody monotherapy, the monotherapy comprising: (a) the following two-week (Q2W) regimen: a first administration of the anti-FGFR2b antibody at a dose of greater than 20 mg / kg to no more than 30 mg / kg, followed by subsequent administrations of the anti-FGFR2b antibody at a dose of 12-20 mg / kg each two weeks after the first administration and Q2W thereafter, wherein the doses of these subsequent administrations are lower than the first administration; or (b) the following two-week (Q2W) regimen: administration of the anti-FGFR2b antibody at a dose of greater than 10 mg / kg to no more than 20 mg / kg, and a single subsequent administration of the anti-FGFR2b antibody at a dose of 5-10 mg / kg one week after the first administration of the anti-FGFR2b antibody.

[0011] In some embodiments of the above methods, or any of the methods of treating a solid tumor described herein, the solid tumor is selected from the group consisting of squamous carcinoma (such as head and neck squamous cell carcinoma), ER-PR-HER2 / neu- ("triple negative") breast cancer, pancreatic ductal adenocarcinoma, intrahepatic bile duct carcinoma, colorectal adenocarcinoma, and gynecological malignancies.

[0012] In some embodiments of the above methods, or any method of treating a solid tumor herein, the solid tumor is selected from the group consisting of squamous carcinoma (such as head and neck squamous cell carcinoma), "triple negative" breast cancer, intrahepatic bile duct carcinoma, lung adenocarcinoma, and gynecological malignancies.

[0013] In some embodiments of the above methods, or any method of treating a solid tumor herein, anti-FGFR2b antibody monotherapy is administered as a second-line or higher-line therapy (such as a third-line or higher-line therapy) for the solid tumor.

[0014] In some embodiments of the above methods, or any of the methods of treating solid tumors herein, the squamous carcinoma is head and neck cancer or squamous esophageal cancer. In some embodiments of the above methods, or any of the methods of treating solid tumors herein, the squamous carcinoma is head and neck squamous cell carcinoma.

[0015] In some embodiments of the above methods, or any of the methods of treating a solid tumor herein, the gynecological malignancy is selected from the group consisting of epithelial ovarian cancer (including fallopian tube cancer and primary peritoneal cancer), endometrial cancer, and cervical cancer.

[0016] In some embodiments of the above methods or any methods of treating a solid tumor herein, the squamous carcinoma is post-platinum-based chemotherapy and / or post-PD-1 inhibitor.

[0017] In some embodiments of the above methods or any methods of treating solid tumors herein, the triple-negative breast cancer is post-chemotherapy, post-PARPi (if BRCA mutated), post-PD-1 inhibitor therapy, and / or post-antitrop-2 therapy.

[0018] In some embodiments of the above methods or any methods of treating a solid tumor described herein, the pancreatic ductal adenocarcinoma is post-platinum-based chemotherapy; the intrahepatic cholangiocarcinoma is post-platinum-based chemotherapy and post-targeted therapy (if eligible for targeted therapy); and / or the colorectal adenocarcinoma is post-bevacizumab therapy, post-oxaliplatin-based chemotherapy, post-irinotecan-based chemotherapy, and / or post-additional prior therapy based on RAS, BRAF, and dMMR / MSI-H status.

[0019] In some embodiments of the above methods or any method of treating a solid tumor herein, the gynecological malignancy is post-platinum-based chemotherapy and / or is platinum chemotherapy-resistant.

[0020] In some embodiments of the above methods or any of the methods for treating a solid tumor herein, cells of the solid tumor overexpress FGFR2b mRNA or protein, or comprise FGFR2 gene amplification.

[0021] In some embodiments of the above methods, or any method of treating a solid tumor herein, the solid tumor overexpresses FGFR2b as determined by immunohistochemistry (IHC).

[0022] In some embodiments of the above methods, or any method of treating a solid tumor herein, cells of the solid tumor are positive for FGFR2b as determined by IHC, optionally wherein at least 5%, 10%, or 20% of the cells are positive for FGFR2b.

[0023] In some embodiments of the above methods, or any method of treating a solid tumor herein, cells of the solid tumor exhibit 2+ and / or 3+ FGFR2b staining as determined by IHC, optionally wherein at least 5%, 10% or 20% of the cells exhibit said FGFR2b staining.

[0024] In some embodiments of the above methods or any method of treating a solid tumor herein, cells of the solid tumor are PD-L1 positive as determined by IHC staining.

[0025] In some embodiments of the above methods, (a) the first administration of the anti-FGFR2b antibody is at a dose greater than 20 mg / kg to no more than 25 mg / kg, and then the anti-FGFR2b antibody is subsequently administered two weeks after the first administration and Q2W thereafter each at a dose of 12-17 mg / kg.

[0026] In some embodiments of the above methods or any method of treating solid tumors herein, (a) the first administration of the anti-FGFR2b antibody is at a dose of 22-25 mg / kg, followed by subsequent administrations of the anti-FGFR2b antibody at a dose of 12-17 mg / kg each two weeks after the first administration and Q2W thereafter.

[0027] In some embodiments of the above methods or any method of treating solid tumors herein, (a) the first administration of the anti-FGFR2b antibody is at a dose of about 22 mg / kg, followed by subsequent administrations of the anti-FGFR2b antibody two weeks after the first administration and Q2W thereafter each at a dose of about 15 mg / kg.

[0028] In some embodiments of the above methods or any methods of treating solid tumors herein, (b) the dose of the anti-FGFR2b antibody is 12-17 mg / kg on a Q2W regimen, and the dose of the subsequent single administration of the anti-FGFR2b antibody one week after the first administration of the anti-FGFR2b antibody is 7-8 mg / kg.

[0029] In some embodiments of the above methods or any methods of treating solid tumors herein, (b) the dose of the Q2W regimen of the anti-FGFR2b antibody is about 15 mg / kg, and the dose of the subsequent single administration of the anti-FGFR2b antibody one week after the first administration of the anti-FGFR2b antibody is about 7.5 mg / kg.

[0030] In some embodiments of the above methods, or any of the methods of treating a solid tumor herein, the anti-FGFR2b antibody is administered intravenously.

[0031] In some embodiments of the above methods or any methods of treating solid tumors herein, the anti-FGFR2b antibody comprises a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 6, HCDR2 of SEQ ID NO: 7, and HCDR3 of SEQ ID NO: 8; and a light chain variable region comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 9, LCDR2 of SEQ ID NO: 10, and LCDR3 of SEQ ID NO: 11.

[0032] In some embodiments of the above methods, or any of the methods of treating a solid tumor herein, the anti-FGFR2b antibody is afucosylated.

[0033] In some embodiments of the above methods or any methods of treating solid tumors herein, the heavy chain variable region of the anti-FGFR2b antibody comprises an amino acid sequence at least 95% identical to SEQ ID NO:4, and the light chain variable region of the anti-FGFR2b antibody comprises an amino acid sequence at least 95% identical to SEQ ID NO:5.

[0034] In some embodiments of the above methods or any methods of treating solid tumors herein, the heavy chain variable region of the anti-FGFR2b antibody comprises the amino acid sequence of SEQ ID NO:4, and the light chain variable region of the anti-FGFR2b antibody comprises the amino acid sequence of SEQ ID NO:5.

[0035] In some embodiments of the above methods or any method of treating a solid tumor herein, the anti-FGFR2b antibody comprises a heavy chain of SEQ ID NO: 1, a light chain of SEQ ID NO: 2, and the anti-FGFR2b antibody lacks fucose at Asn297 (EU numbering).

[0036] In some embodiments of the above methods or any of the methods of treating a solid tumor herein, the anti-FGFR2b antibody is bemarituzumab.

[0037] In some embodiments of the above methods or any method of treating a solid tumor herein, bemarituzumab is administered intravenously, and (a) the first administration of bemarituzumab is at a dose greater than 20 mg / kg to no more than 25 mg / kg, followed by subsequent administrations two weeks after the first administration and Q2W thereafter each at a dose of 12-17 mg / kg.

[0038] In some embodiments of the above methods or any method of treating a solid tumor herein, bemarituzumab is administered intravenously, and (a) the first administration of bemarituzumab is at a dose of 22-25 mg / kg, followed by subsequent administrations two weeks after the first administration and Q2W thereafter each at a dose of 12-17 mg / kg.

[0039] In some embodiments of the above methods or any method of treating a solid tumor herein, bemarituzumab is administered intravenously, and (a) the first administration is at a dose of about 22 mg / kg, followed by subsequent administrations of bemarituzumab two weeks after the first administration and Q2W thereafter each at a dose of about 15 mg / kg.

[0040] In some embodiments of the above methods or any method of treating a solid tumor herein, bamarituzumab is administered intravenously and (b) the dose of bamarituzumab for the Q2W regimen is 12-17 mg / kg and the subsequent single administration of bamarituzumab one week after the first administration is at a dose of 7-8 mg / kg.

[0041] In some embodiments of the above methods or any method of treating a solid tumor herein, bamarituzumab is administered intravenously and (b) the dose of bamarituzumab for the Q2W regimen is about 15 mg / kg and the subsequent single administration of bamarituzumab one week after the first administration is about 7.5 mg / kg. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1A-1B is a diagram of approaches to treating various solid tumor types.

[0043] Figure 2A-2B is a diagram of the amino acid sequence. Figure 2A The amino acid sequences of the anti-FGFR2b antibodies of some embodiments are depicted. Figure 2B The amino acid sequences of FGFR2 of some embodiments are depicted.

[0044] Figures 3A-3I is a graph showing the ADCC response of solid tumor cells treated with bemarituzumab according to some embodiments.

[0045] Figure 4 is a schematic diagram of the activity schedule for the study described in Example 2. DETAILED DESCRIPTION

[0046] Described herein is a method for treating a solid tumor of a subject. The cells of a solid tumor can overexpress FGFR2 isoform FGFR2-IIIb (also referred to as FGFR2b). These methods can include administering anti-FGFR2b antibodies, such as bemarituzumab, to the subject. These methods can include administering anti-FGFR2b antibodies as a monotherapy (e.g., as a monotherapy agent). It can be envisioned herein that anti-FGFR2b antibody monotherapy can be administered via two possible dosing regimens. For example, an anti-FGFR2b antibody monotherapy may include the following biweekly (Q2W) regimen: a first administration of an anti-FGFR2b antibody at a dose of greater than about 20 mg / kg and not more than about 30 mg / kg (such as 20-25 mg / kg, 21-30 mg / kg, or 22-25 mg / kg, or 25-30 mg / kg), followed by subsequent administrations of the anti-FGFR2b antibody at a dose of about 12-20 mg / kg (such as about 12-17 mg / kg (e.g., 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, or 17 mg / kg), about 15-17 mg / kg, or about 18 mg / kg, about 19 mg / kg, or about 20 mg / kg) two weeks after the first administration and Q2W thereafter. For example, anti-FGFR2b antibodies can be administered to subjects at a dose of greater than 20 mg / kg to no more than 25 mg / kg (such as 22-25 mg / kg) Q2W in the first administration, and then each at a dose of 12-17 mg / kg (such as 15-17 mg / kg) Q2W after the first administration for two weeks and thereafter. For example, anti-FGFR2b antibodies can be administered to subjects at a dose of 22-25 mg / kg (such as 22 mg / kg, 23 mg / kg, 24 mg / kg or 25 mg / kg) Q2W in the first administration, and then each at a dose of 15-17 mg / kg (such as 15 mg / kg, 16 mg / kg or 17 mg / kg) Q2W after the first administration for two weeks and thereafter. For example, anti-FGFR2b antibodies can be administered to subjects at a dose of about 22 mg / kg Q2W in the first administration, and then each at a dose of about 15 mg / kg Q2W after the first administration for two weeks and thereafter.

[0047] Additional anti-FGFR2b antibody monotherapy may include the following biweekly (Q2W) regimen: administering the anti-FGFR2b antibody at a dose of greater than about 10 mg / kg and not more than about 20 mg / kg (such as 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg or 20 mg / kg) of the anti-FGFR2b antibody and a single subsequent administration of the anti-FGFR2b antibody at a dose of about 5-10 mg / kg (such as 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg or 10 mg / kg) one week after the first administration of the anti-FGFR2b antibody. For example, the dosage of the Q2W regimen of anti-FGFR2b antibody is 12-17 mg / kg (e.g., 15-17 mg / kg), and the dosage of the single administration of anti-FGFR2b antibody one week after the first administration of anti-FGFR2b antibody is 7-8 mg / kg. For example, the dosage of the Q2W regimen of anti-FGFR2b antibody is about 15 mg / kg, and the dosage of the single administration of anti-FGFR2b antibody one week after the first administration of anti-FGFR2b antibody is about 7.5 mg / kg.

[0048] Alterations in the FGF / FGFR2 signaling pathway have been reported in the literature for a variety of tumor types. Data from The Cancer Genome Atlas (TCGA) reported that FGFR2 overexpression detected by mRNA is common in epithelial cancers. Highly expressing cancers (fragments per kilobase of transcript per million [FPKM]>10) are cholangiocarcinoma (93.3%), ovarian cancer (78.8%), pancreatic cancer (33.9%), triple-negative breast cancer (41.8%), head and neck cancer (57.5%), esophageal squamous cell carcinoma (45.7%), endometrial cancer (46.7%), cervical cancer (29.4%), and colorectal cancer (12.9%). Immunohistochemistry (IHC) showed overexpression (as subjects with FGFR2b2+ / 3+ membrane staining in tumor cells) in ovarian cancer (19%, 95% CI 14%-24%), endometrial cancer (23%, 95% CI 17%-29%), head and neck squamous cell carcinoma (22%, 95% CI 15%-29%), cervical cancer (10%, 95% CI 4%-16%), triple-negative breast cancer (8%, 95% CI 4%-13%), lung adenocarcinoma (6%, 95% CI 1%-11%), and intrahepatic cholangiocarcinoma (iCCA, 1%, 95% CI 0%-3%) (Table 10). Evaluation of bemarituzumab in subjects with FGFR2b overexpressing tumors may improve the outcomes of these subjects by providing targeted inhibition of tumor growth signaling.

[0049] Anti-FGFR2b Antibodies

[0050] As used herein, "antigen binding protein" has its customary and common meaning, as understood by those of ordinary skill in the art in view of the present disclosure. It refers to a protein that specifically binds to a specific antigen. The term encompasses complete antibodies and their derivatives, variants, fragments and mutants. Antigen binding proteins also include bivalent and multivalent (polyvalent / multivalent) constructs and bispecific and multispecific (polyspecific / multispecific) constructs, as well as domain antibodies, scFvs, and membrane-bound receptors and soluble receptors. In some embodiments, the antigen binding protein comprises an antibody, is substantially composed of an antibody, or is composed of an antibody. In any of the methods described herein, an anti-FGFR2b antigen binding protein can be administered to a subject. For example, an antigen binding protein can include an antibody (e.g., bemarituzumab) or be composed of an antibody.

[0051] Antibodies are examples of antigen-binding proteins. As used herein, "antibodies" have their customary and common meanings, as understood by those of ordinary skill in the art in view of the present disclosure. It refers to an immunoglobulin of any isotype that specifically binds to a target antigen, and includes, for example, chimeric antibodies, humanized antibodies, fully human antibodies, and monoclonal antibodies. "Antibodies" are thus a subgenus of an antigen-binding protein. For example, human antibodies or humanized antibodies can be of any isotype, including IgG (including IgG1, IgG2, IgG3, and IgG4 subtypes), IgA (including IgA1 and IgA2 subtypes), IgM, and IgE. Human IgG antibodies will typically contain two full-length heavy chains and two full-length light chains. Antibodies can be derived from a single source only, or can be "chimeric" antibodies, i.e., different parts of an antibody may be derived from two or more different antibodies of the same or different species. It should be understood that once an antibody is obtained from a source, it can be further engineered, for example to enhance stability and folding. Therefore, it should be understood that "human" antibodies can be obtained from a source and can undergo further engineering, such as engineering in the Fc region. Engineered antibodies can still be referred to as a type of human antibody. Similarly, variants of human antibodies, such as those that have undergone affinity maturation, will also be understood to be "human antibodies" unless otherwise specified. In some embodiments, the antigen binding protein comprises, consists essentially of, or consists of a human antibody, a humanized antibody, or a chimeric monoclonal antibody.

[0052] The "heavy chain" of an antigen binding protein (such as an antibody) includes a variable region ("VH") and three constant regions: CH1, CH2 and CH3. The "light chain" of an antigen binding protein (such as an antibody) includes a variable region ("VL") and a constant region ("CL"). Human light chains include kappa chains and lambda chains.

[0053] "Antigen binding region" means a protein or protein portion that specifically binds to a specific antigen. For example, the portion of an antigen binding protein that contains amino acid residues that interact with an antigen and give the antigen binding protein its specificity and affinity for the antigen is called an "antigen binding region". The antigen binding region typically comprises one or more "complementary binding regions" ("CDRs") of an antibody. "CDRs" are amino acid sequences that contribute to antigen binding specificity and affinity. The antigen binding regions of antibody heavy and light chains typically exhibit the same overall structure, comprising a relatively conservative framework region (FR) connected by three CDRs. The CDRs from the two chains of each heavy chain / light chain pair are typically aligned by the framework region to form a structure that specifically binds to a specific epitope on the target protein. From the N-terminus to the C-terminus, naturally occurring light and heavy chain variable regions typically conform to the following order of these elements: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The numbering system has been designed to assign numbers to the amino acids that occupy positions in each of these domains. This numbering system is defined in Kabat, Sequences of Proteins of Immunological Interest (1987 and 1991, National Institutes of Health, Bethesda, Md.); or Chothia and Lesk, 1987, J. Mol. Biol. 196:901-917; Chothia et al., 1989, Nature 342:878-883. In some embodiments, the CDRs of an antigen binding protein are defined according to the definition of Kabat or Chothia.

[0054] Anti-FGFR2b antigen binding proteins (such as antibodies) can be used in the methods described herein.Antibodies can specifically bind to FGFR2b.In the methods of some embodiments, anti-FGFR2b antigen binding proteins bind to FGFR2b with a higher affinity than binding to FGFR2-IIIc.For example, the binding of anti-FGFR2b antibodies to FGFR-IIIc may not be detected.In the methods of some embodiments, anti-FGFR2b antigen binding proteins (e.g., antibodies) bind to FGFR2b, and block or inhibit signal transduction by FGFR2b receptors.For example, the binding of anti-FGFR2b antigen binding proteins (e.g., antibodies) to FGFR2b can inhibit the phosphorylation of MAP kinases downstream of FGFR2 or FGFR2.In the methods of some embodiments, anti-FGFR2b antigen binding proteins (e.g., antibodies) inhibit the binding between FGFR2b and its FGF ligands (such as FGF1 and / or FGF2) after binding to FGFR2b.

[0055] The binding of antigen binding proteins (e.g., antibodies) to FGFR2b and the inhibition of the binding between FGFR2b and FGF can be evaluated, for example, by the ELISA assay described in U.S. Patent No. 8,101,723 or, for example, by the chip-based assay described in Example 2 of WO 2015 / 017600. In some embodiments, the antibody induces ADCC activity, and in some embodiments has enhanced ADCC activity (e.g., as described in WO 2015 / 017600). For example, ADCC activity can be measured as described in Example 3 of WO2015 / 07600. In some embodiments, the antibody can inhibit the growth of human tumors in mouse models, for example, as shown in Example 1 of WO 2017 / 091577. In some embodiments, the anti-FGFR2-IIIb antibody is capable of increasing the number of one or more of PD-L1 positive cells, NK cells, CD3+T cells, CD4+T cells, CD8+T cells and macrophages in tumor tissue in a mouse tumor model compared to a control, for example, as described in Example 2 of International Application No. WO 2017 / 091577.

[0056] Any anti-FGFR2b antibody described herein can be afucosylated. For example, the antibody can be an IgG1 or IgG3 antibody lacking fucose at Asn297. As used herein, an "afucosylated" antibody or an antibody "lacking fucose" refers to an IgG1 or IgG3 isotype antibody lacking fucose in its constant region glycosylation. Glycosylation of human IgG1 or IgG3 occurs at Asn297 (N297; EU numbering of Fc region residues), and the core fucosylated bi-branched complex oligosaccharide glycosylation terminates with up to 2 Gal residues. In some embodiments, the afucosylated antibody lacks fucose at Asn297. Depending on the number of terminal Gal residues, these structures are named G0, G1 (α1,6 or α1,3) or G2 glycan residues. See, for example, Raju, TS, BioProcess Int. [International Journal of Biopharmaceutical Engineering Technology] 1: 44-53 (2003). CHO-type glycosylation of antibody Fc is described, for example, in Routier, FH, Glycoconjugate J. 14:201-207 (1997). It will be appreciated that compositions comprising monoclonal antibodies are typically heterogeneous. Indeed, the methods comprising administering the afucosylated anti-FGFR2 antibodies described herein may also comprise administering some afucosylated antibody molecules. Within a population of antibodies, an antibody is considered afucosylated if <5% of the antibodies in the population contain fucose at Asn297. For example, in some embodiments, greater than 95% of the anti-FGFR2b antibody molecules administered to a subject are afucosylated. For example, in some embodiments, at least 96%, 97%, or 99% of the anti-FGFR2b antibody molecules administered to a subject may be afucosylated. Other antibodies useful in the examples herein include those described in U.S. Patent Publication No. 2015 / 0050273, which describes certain afucosylated anti-FGFR2b antibodies and is incorporated herein by reference in its entirety.

[0057] In some embodiments, in the presence of human effector cells, the afucosylated anti-FGFR2b antibody mediates antibody-dependent cell-mediated cytotoxicity (ADCC) more effectively than an antibody comprising fucose having the same amino acid sequence. Typically, ADCC activity can be determined using an in vitro ADCC assay disclosed in U.S. Patent Publication No. 2015 / 0050273, but other assays or methods for determining ADCC activity, such as in animal models, are contemplated.

[0058] Exemplary sequences of anti-FGFR2b antibodies of some embodiments are Figure 2AIn some embodiments of the method, the anti-FGFR2b antibody comprises at least one, two, three, four, five or six complementary determining regions (CDRs) selected from (a) HCDR1 of SEQ ID NO: 6; (b) HCDR2 of SEQ ID NO: 7; (c) HCDR3 of SEQ ID NO: 8; (d) LCDR1 of SEQ ID NO: 9; (e) LCDR2 of SEQ ID NO: 10; and (f) LCDR3 of SEQ ID NO: 11. Anti-FGFR2b may comprise a heavy chain comprising a heavy chain variable region comprising HCDR1 of SEQ ID NO: 6, HCDR2 of SEQ ID NO: 7, and HCDR3 of SEQ ID NO: 8; and may further comprise a light chain comprising a light chain variable region comprising LCDR1 of SEQ ID NO: 9, LCDR2 of SEQ ID NO: 8, and LCDR3 of SEQ ID NO: 9. In some embodiments of the method, the heavy chain variable region is at least 90% identical to SEQ ID NO: 4, and the light chain variable region is at least 90% identical to SEQ ID NO: 5. In some embodiments of the method, the heavy chain variable region is at least 95% identical to SEQ ID NO: 4, and the light chain variable region is at least 95% identical to SEQ ID NO: 5. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 4, and the light chain variable region comprises SEQ ID NO: 5. In some embodiments of the method, the heavy chain comprises SEQ ID NO: 2, and the light chain comprises SEQ ID NO: 3. Any anti-FGFR2 antibody described herein can be afucosylated. For example, the antibody can be an IgG1 or IgG3 antibody lacking fucose at Asn297. In some embodiments of the method, the anti-FGFR2b antibody is bemarituzumab.

[0059] In some embodiments of the method, the anti-FGFR2b antibody comprises a heavy chain variable region comprising SEQ ID NO: 4 and a light chain variable region comprising SEQ ID NO: 5. It is also contemplated that in some embodiments, the anti-FGFR2b antibody comprises one or more substitutions, insertions or deletions compared to SEQ ID NO: 4 and / or SEQ ID NO: 5, and continues to bind to FGFR2b. For example, the anti-FGFR2b antibody comprises one or more substitutions, insertions or deletions compared to SEQ ID NO: 4 and / or SEQ ID NO: 5, and can bind to FGFR2b with an affinity (as measured by surface plasmon resonance) that is not less than one order of magnitude lower than the affinity of a reference FGFR2b antibody, the reference antibody comprising a heavy chain variable region comprising SEQ ID NO: 4 and a light chain variable region comprising SEQ ID NO: 5. In some embodiments of the methods, the anti-FGFR2b antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 96%, 98% or 99% identity to SEQ ID NO: 4, and the light chain variable region having at least 90% identity to SEQ ID NO: 5. In some embodiments of the methods, the anti-FGFR2b antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 96%, 98% or 99% identity to SEQ ID NO: 4, and the light chain variable region having at least 91% identity to SEQ ID NO: 5. In some embodiments of the methods, the anti-FGFR2b antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 96%, 98% or 99% identity to SEQ ID NO: 4, and the light chain variable region having at least 95% identity to SEQ ID NO: 5. In some embodiments of the methods, the anti-FGFR2b antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 96%, 98% or 99% identity to SEQ ID NO: 4, and the light chain variable region having at least 97% identity to SEQ ID NO: 5. In some embodiments of the methods, the anti-FGFR2b antibody comprises a heavy chain variable region and a light chain variable region of SEQ ID NO:5, wherein the heavy chain variable region is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 96%, 98% or 99% identical to SEQ ID NO:4.In the methods of some embodiments, the anti-FGFR2b antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region having at least 90% identity with SEQ ID NO: 4, and the light chain variable region having at least 90% identity with SEQ ID NO: 5. In the methods of some embodiments, the heavy chain variable region has at least 95% identity with SEQ ID NO: 4, and the light chain variable region has at least 95% identity with SEQ ID NO: 5. In some embodiments, a total of 1 to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 4. Substitutions, insertions or deletions may occur in regions other than CDRs (i.e., in FRs). In the methods of some embodiments, a total of 1 to 10, 1 to 5, or 1 to 3 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 5. Substitutions, insertions or deletions may occur in regions other than CDRs (i.e., in FRs). In some embodiments, a total of 1 to 10, 1 to 5, or 1 to 3 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 4. Substitutions, insertions or deletions may occur in regions outside the CDRs (i.e., in the FRs). In the methods of some embodiments, up to 10, up to 5, or up to 3 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:5, and up to 10 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:4. Substitutions, insertions or deletions may occur in regions outside the CDRs (i.e., in the FRs). In the methods of some embodiments, up to 10, up to 5, or up to 3 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:5, and up to 5 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:4. Substitutions, insertions or deletions may occur in regions outside the CDRs (i.e., in the FRs). In the methods of some embodiments, up to 10, up to 5, or up to 3 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:5, and up to 3 amino acids have been substituted, inserted and / or deleted in SEQ ID NO:4. Substitutions, insertions or deletions may occur in regions other than CDRs (i.e., in FRs). In some embodiments, a total of 1 to 10, 1 to 5, or 1 to 3 amino acids have been substituted, inserted and / or deleted in SEQ ID NO: 4. Any anti-FGFR2 antibody described herein may be afucosylated. For example, the antibody may be an IgG1 or IgG3 antibody lacking fucose at Asn297.

[0060] Other examples of anti-FGFR2b antibodies are HuGAL-FR21, GAL-FR22 and GAL-FR23 antibodies described in U.S. Patent No. 8,101,723B2, which is incorporated herein by reference in its entirety. Figures 13 and 14 of U.S. Patent No. 8,101,723B2 show the amino acid sequences of the variable regions and full-length mature antibody chains of HuGAL-FR21, and are incorporated herein by reference. The heavy chain variable region sequence of antibody HuGAL-FR21 is underlined in Figure 13 of U.S. Patent No. 8,101,723B2, and is expressly incorporated herein by reference. The light chain and heavy chain variable regions of GAL-FR22 are provided as (e.g.) SEQ ID NOs: 7 and 8 in patent No. 8,101,723B2, and Kabat CDRs and light chain and heavy chain variable regions are also provided in Figure 16 of the patent, which is incorporated herein by reference. The hybridomas producing GAL-FR21, GAL-FR22, and GAL-FR23 were deposited at the American Type Culture Collection, PO Box 1549, Manassas VA, USA, 20108, with ATCC numbers 9586, 9587, and 9408, respectively, on November 6, 2008, November 6, and August 12, 2008. Thus, in some embodiments, the FGFR2 antibody is an antibody comprising the amino acid sequence of an antibody obtained from one of these three hybridoma strains.

[0061] Bemarituzumab is a non-fucosylated humanized monoclonal antibody that targets fibroblast growth factor (FGF) receptor isoform 2b (FGFR2b) and has a dual mechanism of FGF binding inhibition and antibody-dependent cellular toxicity. The anti-FGFR2b antibody of any one of the methods described herein can be bemarituzumab. Bemarituzumab comprises a heavy chain of SEQ ID NO:2 and a light chain of SEQ ID NO:3. In the methods of some embodiments, the anti-FGFR2 antibody comprises a heavy chain of SEQID NO:2 and a light chain of SEQ ID NO:3, and is non-fucosylated. In the methods of some embodiments, the anti-FGFR2b antibody is bemarituzumab. In the methods of some embodiments, the anti-FGFR2b antibody comprises HCDR1-3 and LCDR1-3 of bemarituzumab. Bemarituzumab can be produced in a Chinese hamster ovary cell line lacking the FUT8 gene, so the produced antibody is glycosylated but lacks core fucose in the polysaccharide portion of the antibody. The absence of core fucose results in a higher affinity for the Fc receptor FcγRIIIa compared to the fucosylated molecule and potentially enhances immune cell-mediated tumor cell killing.

[0062] Bemarituzumab inhibits FGFR2b phosphorylation stimulated by FGF ligands and cell proliferation of FGFR2b overexpressing gastric cancer, breast cancer and non-small cell lung cancer cell lines in cell culture. Bemarituzumab also inhibits tumor growth in FGFR2b overexpressing gastric and breast xenograft models. Without being limited by theory, it is conceivable that the mechanism of action of bemarituzumab may include blocking ligand binding and downstream signal transduction, reducing the expression of FGFR2b driver protein and / or enhancing ADCC. In addition, without being limited by theory, it is conceivable that because bemarituzumab is specific to FGFR2b receptors, it will not interfere with the signal transduction of other FGF / FGFRs (including FGFR2c). Compared with FGFR tyrosine kinase inhibitors (TKI), bemarituzumab does not inhibit FGF23 signal transduction. FGF23 is a ligand involved in calcium / phosphate metabolism, so treatment with bemarituzumab is not associated with hyperphosphatemia associated with FGFR TKIs (Catenacci et al., 2020; Dienstmann et al., 2014; Sequist et al., 2014; Andre et al., 2013; Brown et al., 2005).

[0063] Bemarituzumab monotherapy has been studied in a Phase 1 dose-finding study (FPA144-001) and in combination with mFOLFOX6 chemotherapy in FGFR2b-positive gastric cancer in the FIGHT study. The efficacy of bemarituzumab correlates with the degree of FGFR2b overexpression in gastric cancer as detected by immunohistochemistry (IHC), and has demonstrated a manageable safety profile in combination with mFOLFOX6. Genomic and IHC data suggest that other cancers, including gastric cancer, may also have significant rates of FGFR2b overexpression. Bemarituzumab blocks FGFR2b phosphorylation, downregulates the receptor, and inhibits downstream signaling. The effects on downstream signaling were measured by studying the phosphorylation of proteins that are directly phosphorylated by the FGFR2 protein, FGFR substrate-2 (FRS2). Each of these mechanisms has been explored in vitro and in vivo and, without being limited by theory, appears to contribute to the antitumor activity of bemarituzumab. In a human tumor xenograft model with FGFR2b overexpression, bemarituzumab demonstrated dose-related antitumor activity, with regressions and complete responses at well-tolerated doses.

[0064] Bemmarituzumab exhibited consistent pharmacokinetic (PK) behavior following intravenous (IV) administration in rats and cynomolgus monkeys, and the PK profiles observed were consistent across all studies. The half-life was dose-dependent, ranging from 0.8 days at the lowest dose (1 to 1.5 mg / kg) to at least 8 days at the highest dose (100 to 150 mg / kg) tested in cynomolgus monkeys. Bemmarituzumab exhibited dose-dependent, nonlinear PK, marked by faster clearance at the end of the plasma concentration-time profile and greater than dose-proportional increases in exposure (area under the concentration-time curve [AUC]) with increasing doses. Target-mediated clearance was saturable, marked by dose-proportional increases in exposure at doses above this level when administered at weekly intervals. PK studies supporting the toxicokinetic studies showed a dose-dependent increase in exposure (AUC), supporting the reliability of these studies in assessing toxicity. Through prenatal and postnatal development studies, significant reproductive and developmental toxicity was observed at all dose levels (5 to 100 mg / kg / dose) in embryo-fetal development. Thus, it is conceivable that, in some embodiments, subjects treated with bemarituzumab do not become pregnant.

[0065] Bemarituzumab has demonstrated an acceptable safety profile. Identified risks when used in combination with mFOLFOX6 include corneal toxicity, infusion-related reactions, gastrointestinal toxicity (stomatitis and mucosal inflammation), nail toxicity, and elevated AST and ALT. Corneal events seen with bemarituzumab treatment are very common, with the most common adverse event being dry eye. Although almost all events are non-serious, grade 3 events (such as ulcerative keratitis and punctate keratitis) have been observed, which can lead to decreased visual acuity. Most corneal events are usually resolved with interruption or discontinuation of treatment and standard care interventions for corneal events. Thus, it is conceivable that, in some embodiments, subjects treated with bemarituzumab are further treated with ocular lubricants. Ocular lubricants can be applied prophylactically to reduce the risk of corneal events.

[0066] In some methods described herein, bemarituzumab can be provided in a drug product composition comprising or consisting essentially of an aqueous solution comprising 20 mg / mL bemarituzumab, L-histidine, sucrose, and polysorbate 20 at a pH of 6.0. For example, the solution can comprise, consist essentially of, or consist of 20 mg / mL bemarituzumab, 20 mM L-histidine, 270 nM sucrose, and 0.01% (w / v) polysorbate 20 at a pH of 6.0.

[0067] Anti-FGFR2b antibodies (such as bemarituzumab) can be administered intravenously in the methods described herein.

[0068] Methods for treating solid tumors overexpressing FGFR2b

[0069] Solid Tumors

[0070] Described herein are methods for treating solid tumors in subjects such as squamous cell carcinoma, ER-PR-HER2 / neu- ("triple negative") breast cancer, intrahepatic bile duct carcinoma, lung adenocarcinoma, and gynecological malignancies. Squamous cell carcinoma can be, for example, head and neck cancer. Gynecological malignancies can be, for example, ovarian epithelial cancer (including fallopian tube cancer and primary peritoneal cancer), endometrial cancer, or cervical cancer. In some embodiments, the solid tumor is selected from squamous cell carcinoma, triple negative breast cancer, pancreatic ductal adenocarcinoma, intrahepatic bile duct carcinoma, colorectal adenocarcinoma, and gynecological malignancies.

[0071] In certain embodiments, anti-FGFR2b antibody monotherapy is used as the second-line or second-line therapy (such as third-line or third-line therapy) of solid tumor.Term " second-line therapy " as used herein refers to the treatment of disease or illness after failure, stop working or have the side effect that patient cannot tolerate in initial treatment (" first-line " treatment or therapy).Therapy or treatment applied after second-line therapy can be referred to as "second-line or more" therapy, or represented by numbers (for example, "third-line" or "four-line" therapy).In certain embodiments, anti-FGFR2b antibody monotherapy is used as second-line or second-line therapy after first-line therapy including, for example, chemotherapy, radiation and / or immunotherapy.For example, solid tumor can be based on chemotherapy after platinum, after PD-1 inhibitor therapy, after poly (ADP-ribose) polymerase inhibitor (PARPi) therapy (if BRCA mutation), after anti-trop-2 therapy or after targeted therapy.In certain embodiments, solid tumor can be based on chemotherapy after platinum and / or squamous carcinoma after PD-1 inhibitor. In some embodiments, the solid tumor is a triple-negative breast cancer, which is after chemotherapy, after PARPi (if BRCA mutation), after PD-1 inhibitor therapy and / or after anti-trop-2 therapy. In some embodiments, the solid tumor can be a pancreatic ductal adenocarcinoma after platinum-based chemotherapy. In some embodiments, the solid tumor can be intrahepatic cholangiocarcinoma after platinum-based chemotherapy and targeted therapy (if the conditions of targeted therapy are met). In some embodiments, the solid tumor can be colorectal adenocarcinoma, which is after bevacizumab therapy, after oxaliplatin-based chemotherapy, after irinotecan-based chemotherapy, and / or after another previous therapy based on RAS, BRAF and dMMR / MSI-H status. In some embodiments, the solid tumor can be a gynecological malignancy after platinum-based chemotherapy and / or platinum chemotherapy resistance.

[0072] Methods comprising administering an anti-FGFR2b antibody

[0073] Methods described herein may include administering anti-FGFR2b antibody monotherapy.For example, anti-FGFR2b antibody monotherapy may include following biweekly (Q2W) scheme: administer anti-FGFR2b antibody for the first time with a dosage greater than 20mg / kg to no more than 30mg / kg, then administer anti-FGFR2b antibody subsequently with a dosage of 12-20mg / kg each at Q2W after the first administration for two weeks and thereafter, wherein these subsequently administered dosages are lower than the first administration.In another example, anti-FGFR2b antibody monotherapy may include following biweekly (Q2W) scheme: administer anti-FGFR2b antibody with a dosage greater than 10mg / kg to no more than 20mg / kg, and administer anti-FGFR2b antibody one week after the first administration of anti-FGFR2b antibody, with a single subsequent administration of anti-FGFR2b antibody at a dosage of 5-10mg / kg.Subsequent administration or dosage of anti-FGFR2b antibody may be referred to as "intervention" dosage.

[0074] In some methods, anti-FGFR2b antibody is administered to the subject with a dosage Q2W greater than 20mg / kg to no more than 30mg / kg (such as greater than 20mg / kg to no more than 25mg / kg). In some methods, anti-FGFR2b antibody is administered to the subject with a dosage Q2W of about 22-25mg / kg (for example, 22mg / kg, 23mg / kg, 24mg / kg, 25mg / kg, or a range defined by any two of the aforementioned values). In some methods, anti-FGFR2b antibody is administered to the subject with a dosage Q2W of 22mg / kg. According to some methods described herein, the additional dose or "intervention" dose of anti-FGFR2b antibody can be 12-20mg / kg, such as 12-17mg / kg, and can be administered Q2W two weeks after the first administration of anti-FGFR2b antibody and thereafter. According to some methods described herein, the first administration of anti-FGFR2b antibody can be followed by administration of anti-FGFR2b antibody two weeks after the first administration and Q2W thereafter, each at a dosage of about 12 mg / kg, about 13 mg / kg, about 14 mg / kg, about 15 mg / kg, about 16 mg / kg, about 17 mg / kg, or a range defined by any two of the aforementioned values. By way of example, an additional dose or "intervention" dose can be about 15 mg / kg.

[0075] In some methods, anti-FGFR2b antibody is administered to the subject with a dosage Q2W greater than 10mg / kg to no more than 20mg / kg. In some methods, anti-FGFR2b antibody is administered to the subject with a dosage Q2W of about 12-17mg / kg (e.g., 12mg / kg, 13mg / kg, 14mg / kg, 15mg / kg, 16mg / kg, 17mg / kg, or the scope defined by any two of the aforementioned values). In some methods, anti-FGFR2b antibody is administered to the subject with a dosage Q2W of 15mg / kg. In certain embodiments, one week after the first administration of anti-FGFR2b antibody, the method may include a single subsequent administration of anti-FGFR2b antibody with a dosage of 5-10mg / kg (e.g., 5mg / kg, 6mg / kg, 7mg / kg, 8mg / kg, 9mg / kg, 10mg / kg, or the scope defined by any two of the aforementioned values). By way of example, the additional dose or "intervention" dose may be about 7-8 mg / kg, such as about 7.5 mg / kg.

[0076] For any of the methods described herein, the anti-FGFR2b antibody can be bemarituzumab.A method of treating a solid tumor in a subject according to some embodiments is depicted in FIG. 1 .

[0077] Methods according to some embodiments describe a study evaluating the safety and efficacy of bemarituzumab monotherapy in subjects with multiple solid tumors and relapsed / refractory unresectable and / or metastatic disease that overexpress FGFR2b. The study may include dosing and scheduling of bemarituzumab as described in Example 2.

[0078] For any method for treating solid tumors as described herein, the cells of the subject's solid tumor can express FGFR2b. For example, the cells of the subject's solid tumor can overexpress FGFR2b protein, overexpress FGFR2b mRNA, or include FGFR2b gene amplification. In some methods, the cells of solid tumors express FGFR2b protein, as determined by immunohistochemistry (IHC). For example, at least 5% (for example, 5%, 10% or 20%) of the subject's solid tumor can be positive for FGFR2b, as determined by IHC. For example, the cells of the subject's solid tumor can have 2+ and / or 3+ FGFR2b staining intensity. For example, at least 5% (for example, at least 5%, 10% or 20%) of the solid tumor cells can have 1+, 2+ or 3+ FGFR2b staining intensity. If the cells of the subject's solid tumor may have a FGFR2b staining intensity of 2+ or 3+, or if at least 5% (e.g., at least 5%, 10% or 20%) of the solid tumor cells may have a FGFR2b staining intensity of 1+, 2+ or 3+, then the subject's solid tumor may be considered to overexpress FGFR2b. For example, at least 5% of the cells of the subject's solid tumor may have a FGFR2b staining intensity of 2+ and / or 3+. For example, at least 10% of the cells of the subject's solid tumor may have a FGFR2b staining intensity of 2+ and / or 3+. It is conceivable that subjects with solid tumors that overexpress FGFR2b may particularly benefit from treatments including administering anti-FGFR2b antibodies described herein (such as bemarituzumab). Optionally, the PD-L1 expression of cells of solid tumors is also evaluated, for example, by IHC.

[0079] The following examples further illustrate the invention but, of course, should not be construed as limiting its scope in any way.

[0080] Example 1: Administration of Bemarituzumab to Breast Cancer and Lung Cancer Cell Lines

[0081] ADCC activity of bemarituzumab was measured in vitro in squamous lung cancer cell lines and breast cancer cell lines that were determined to exhibit surface expression of FGFR2b by flow cytometry. FGFR2b mRNA expression [ENST00000457416.6[FPKQ]] and surface expression of FGFR2b protein were evaluated by flow cytometry in squamous lung cancer cell lines (KNS-62, LC1F, HARA, EPLC-272H, SW900, NCIH2170, LUDLU1, and SW1573) and triple negative breast cancer (TNBC) cell lines (HCC1569, HCC1806, HCC38, HCC1187, BT20, and HCC1937). As positive controls, gastric cancer cell lines SNU16-Luc, SNU16, and KATOIII were also evaluated. In flow cytometry experiments, cells were incubated with bemarituzumab or a control antibody of the same isotype, and binding was detected using an anti-human IgG1 antibody conjugated to allophycocyanin (APC). The mean fluorescence intensity (MFI) was quantified by flow cytometry. As shown in Table 1 below, the MFI of squamous lung cancer cell lines KNS-62, EPLC-272H, LC1F, HARA, SW900, and LUDLU1 was at least 10, as was the case for triple-negative breast cancer (TNBC) cell lines HCC1569, HCC1806, HCC38, BT20, and HCC1937.

[0082] The effect of bemarituzumab on antibody-dependent cellular cytotoxicity (ADCC) was evaluated in each cell line. Cancer cell lines were co-cultured with Jurkat-Luc effector cells in 96-well plates with a fixed number of effector cells (75,000 cells per well) and a ratio of effector cells to target cells of 2.5:1 or 5:1. Cells were treated with 20 mg / mL of bemarituzumab and then incubated at 37°C for 20 hours. ADCC was assessed using the ADCCReporter Bioassay from Promega (G7018), which uses a luminescent readout. ADCC curves were plotted at Figures 3A-3I ADCC activity was observed in squamous lung cancer cell lines and breast cancer cell lines that exhibited surface expression of FGFR2b above 10 MFI. Therefore, it can be concluded that bemarituzumab is able to induce ADCC in FGFR2b-positive triple-negative breast cancer cells and squamous lung cancer cells.

[0083] Table 1

[0084]

[0085] Example 2: Phase 1b / 2 basket study of bemarituzumab monotherapy in solid tumors overexpressing FGFR2b

[0086] This example describes a Phase 1b / 2 open-label, multicenter exploratory, signal discovery basket study evaluating the efficacy and safety of bemarituzumab monotherapy in subjects with multiple solid tumors and relapsed / refractory unresectable and / or metastatic disease that overexpress FGFR2b.

[0087] The study includes a prescreening period to demonstrate FGFR2b overexpression via central testing, a 28-day screening period, a treatment period, a safety follow-up (SFU) period, and a long-term follow-up (LTFU) period. Subjects who discontinue bemarituzumab will receive an SFU visit 28 (+3) days after the last dose of study treatment. In addition, starting with the first dose of bemarituzumab, subjects will receive survival LTFU approximately every 3 months (±1 month) after the SFU visit for up to 2 years. Subjects will be treated until disease progression, unacceptable toxicity, subject request, or death (whichever occurs first).

[0088] Investigators will perform radiographic assessments according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 every 8 weeks (±7 days) from Day 1 of Cycle 1 until Week 56, and then every 12 weeks (±14 days) until radiographic progression or initiation of subsequent anticancer therapy. The primary and secondary objectives and endpoints are summarized in Table 2 below.

[0089] Table 2

[0090]

[0091]

[0092]

[0093] The study consists of 2 parts: monotherapy dose exploration across tumor types (i.e., a total of 9 to 18 subjects regardless of tumor type) (Part 1, Phase 1b), followed by monotherapy dose expansion (Part 2, Phase 2) for each of the following 8 tumor cohorts at the dose level selected in Part 1. For both parts of the study, tumor samples from subjects demonstrating FGFR2b overexpression prior to entry into the study are required. It is recommended to use tumor specimens collected after completion of the most recent cancer therapy.

[0094] This study will enroll subjects into 8 tumor cohorts based on cancer type:

[0095] 1. Head and neck squamous cell carcinoma

[0096] 2. Triple negative breast cancer (ER-, PR-, HER2 / neu-)

[0097] 3. Intrahepatic bile duct carcinoma

[0098] 4. Lung adenocarcinoma

[0099] 5. Ovarian epithelial cancer, including fallopian tube cancer and primary peritoneal cancer

[0100] 6. Endometrial adenocarcinoma

[0101] 7. Cervical cancer

[0102] 8. Other solid tumors

[0103] The requirements for the number of prior lines of therapy varied according to the study cohort as outlined in the inclusion criteria below.

[0104] The study may be amended to add or remove cohorts based on enrollment rates, prevalence of FGFR2b overexpression in prescreening, preliminary efficacy and safety data, and evolving data on other potential solid tumor indications for FGFR2b overexpression. Study cohorts may be amended to specific histologic subtypes based on emerging data on FGFR2b overexpression and response rates. Due to the likely low frequency of FGFR2b overexpression in specific disease settings, recruitment / enrollment in any of the above cohorts may present some challenges. Therefore, the Sponsor reserves the right to stop recruitment / enrollment in any cohort due to slow or no accrual. Cohort 10 (Other Solid Tumors) will close to enrollment when all other cohorts are closed, regardless of the number of patients enrolled at that time.

[0105] Part 1 begins at dose level 1 (22 mg / kg intravenously [IV] on Day 1 of Cycle 1, then 15 mg / kg IV every 2 weeks [Q2W] starting on Day 15). The study DLT evaluation period is 28 days. A Dose Level Review Team (DLRT) meeting will be held once 3 to 6 subjects have completed the DLT evaluation period. Based on observed safety data, the following scenarios may occur: (1) additional enrollment to dose level 1; or (2) dose reduction to dose level 1A; or (3) initiation of part 2 of the study. A modified toxicity probability interval (mTPI)-2 design using a target toxicity probability of 0.25 and an acceptable toxicity probability interval (0.20, 0.30) will be used to derive the escalation / decrement guidelines. Part 1 will continue until the maximum sample size of 18 is reached or the number of subjects treated at a given dose level reaches 9 and the mTPI-2 algorithm indicates to maintain that dose level. In addition, 3 to 6 Japanese subjects will be enrolled as part of the initial dose evaluation in Part 1 or as a backfill if the recommended Phase 2 dose (RP2D) is determined. Japanese subjects may be enrolled in Part 2 once the DLRT deems the global RP2D safe for Japanese subjects.

[0106] Number of subjects

[0107] A total of 288 to 303 subjects will be enrolled in the study, with 9 to 18 subjects in Part 1, regardless of tumor cohort, and the possibility of up to 6 additional Japanese subjects. In Part 2, up to 36 subjects will be enrolled in each of the 10 planned tumor cohorts (subjects in Part 1 who are assigned to the same dose level used in Part 2 will make up the 36 subjects total, so some tumor cohorts may enroll fewer than 36 subjects in Part 2).

[0108] Summary of Subject Eligibility Criteria

[0109] Subjects were ≥18 years of age (or national age of majority, whichever was older) with histologically or cytologically confirmed cancer of the type outlined in the study design. Subjects must have unresectable locally advanced or metastatic disease. Subjects must have FGFR2b overexpression as determined by centrally performed immunohistochemistry (IHC) testing. All subjects must have measurable disease according to RECIST v.1.1.

[0110] treat

[0111] The planned dose of bemarituzumab in this study (dose level 1) is 22 mg / kg IV on Day 1 of Cycle 1, followed by 15 mg / kg IV Q2W starting on Day 15 thereafter. One treatment cycle will be 14 days. If dose reduction from dose level 1 is required, dosing level 1A can be explored, consisting of bemarituzumab 15 mg / kg IV Q2W starting on Day 1 of Cycle 1 plus 1 additional 7.5 mg / kg dose on Day 8 of Cycle 1 only.

[0112] Statistical considerations

[0113] Sample size considerations

[0114] In Part 1, if the true DLT rate in the 9 subjects treated at a dose level was 25%, the probability of observing at least 1 DLT was 92%. In Part 2, the Clopper-Pearson Exact 95% lower confidence limits corresponding to the observed objective response rates (ORR) of 11.1%, 16.7%, 22.2%, 27.8%, and 33.3% in 36 subjects were 3.1%, 6.4%, 10.1%, 14.2%, and 18.6%, respectively; subjects in Part 1 assigned to the same dose level used in Part 2 would constitute a total of 36 subjects.

[0115] Interim Analysis

[0116] In Part 1, the DLRT will be convened to review all available safety, tolerability, laboratory, and PK data during and after completion of Part 1 (28 days after enrollment of the last subject in Part 1).

[0117] In Part 2, the Data Review Team (DRT) will review safety data after a specified number of subjects in the full analysis set (regardless of tumor type) have had the opportunity to be followed for 8 weeks. To make this assessment, the DRT will use their clinical judgment in reviewing all relevant safety data and use stopping guidelines based on a Bayesian posterior probability of >85% (i.e., the posterior probability of a Grade 4+ treatment-related adverse event rate exceeding 20% ​​using a beta(1,1) prior distribution).

[0118] In addition to the safety data review, the DRT will oversee non-binding futility interim analyses (two scans) that occur after the first 12 and 24 subjects scheduled to be dosed in a given tumor cohort have had an opportunity to complete 16-week disease assessments. Enrollment will not be suspended for futility analyses. Stopping for futility will be based on a predicted probability of <20% that the ORR will be >15% after all 36 subjects are enrolled and have had an opportunity to complete 16-week disease assessments. A non-informative beta (1, 1) prior distribution will be used. If 0 of 12 subjects or ≤1 of 24 subjects have an OR, the cohort may be stopped for futility. Additional interim analyses of selected efficacy and safety endpoints will be performed by tumor cohort once all subjects enrolled in a tumor cohort have had an opportunity to complete 16-week disease assessments, prior to the primary analysis of the entire study.

[0119] Analytical methods

[0120] The primary analysis of efficacy and safety will be based on all enrolled subjects who received at least one dose of the investigational product. Continuous variables will be described using mean, median, quartiles, minimum, and maximum values. Categorical data will be summarized using frequency counts and percentages. Response rates will be summarized using exact 95% confidence intervals. Event endpoint times will be summarized using Kaplan-Meier (KM) quartiles and ratios at selected time points. The final analysis will be performed when all subjects in all tumor cohorts have completed the study. Event endpoint times will be updated with further follow-up for the final analysis. Statistical assumptions were not tested in this study.

[0121] Rationale for bemarituzumab dosing

[0122] For phase 1 of this study, bemarituzumab 22 mg / kg on day 1 of cycle 1 was selected based on the following data:

[0123] In the Phase 1 FPA144-001 monotherapy dose-escalation study, bemarituzumab demonstrated linear clearance from 1 mg / kg to 15 mg / kg in subjects with solid tumors, including gastric cancer. Within the linear dose range, the maximum observed serum concentration (C 最大 ) and AUC increased in proportion to the dose. The half-life estimated by non-compartmental analysis at 1 mg / kg to 15 mg / kg was 6.01 to 11.7 days, which supports Q2W or less frequent dosing.

[0124] During the dose interval (C 谷 The target bemarituzumab concentration of ≥60 μg / mL observed at the end of treatment was derived from nonclinical studies, including binding affinity to human FGFR2b-Fc and human FcγRIIIa (V158), in vitro receptor occupancy, and in vivo efficacy studies.

[0125] Support 60μg / mL should be the target minimum C 谷 Based on the hypothesis that all subjects with FGFR2b overexpression who demonstrated a partial response (PR) in the FIH FPA144-001 trial would achieve a target C of ≥60 μg / mL 谷,ss Of all subjects treated with 15 mg / kg Q2W in Study FPA144-001, 23 of 51 subjects achieved target C on Day 15. 谷 By week 8 (steady state), 14 of 16 subjects achieved target C ≥ 60 μg / mL at the same dose. 谷 .

[0126] Due to the shortening of the target C 谷 The timing of the level may help maximize the potential benefit of bemarituzumab, so an additional 7.5 mg / kg dose on day 8 of cycle 1 was added to reach the target.

[0127] Observed PK data from the Phase 1 portion of Study FPA144-004 demonstrated that all subjects with PK data treated at 15 mg / kg Q2W with 1 additional 7.5 mg / kg dose on Day 8 of Cycle 1 achieved Target C on Day 15 谷 concentration, and C 最大 This is within the range observed in Study FPA144-001. Therefore, the addition of a single 7.5 mg / kg dose on Day 8 of Cycle 1 minimizes the need to achieve Target C. 谷 time without increasing C 最 big.

[0128] The FPA144-004 study of 15 mg / kg of bemarituzumab given Q2W in combination with mFOLFOX6 with an additional 7.5 mg / kg dose on Day 8 of Cycle 1 achieved pre-specified statistical significance in all three of its pre-specified efficacy endpoints, including objective ORR, PFS, and OS, in FGFR2b-positive, non-HER2-positive subjects who were advanced first-line treatment for gastric and gastroesophageal junction cancer. In addition, a population PK analysis using PK data from studies FPA144-001, FPA144-002, and FPA144-004 showed that although baseline weight, baseline albumin, sex, and combination therapy were identified as statistically significant covariates for the PK of bemarituzumab, no covariates were expected to have a clinically meaningful effect on bemarituzumab exposure in the gastric and gastroesophageal junction cancer populations and treatments. No dose adjustment is required based on any of these factors. In addition, preliminary exposure-response analysis demonstrated that bemarituzumab 15 mg / kg Q2W with 1 additional 7.5 mg / kg dose on day 8 of cycle 1 adequately balanced safety and efficacy based on a manageable safety profile and favorable efficacy data.

[0129] Rationale for loading dose

[0130] In this study, a loading dose of 22 mg / kg on Day 1 of Cycle 1 was added (prior to 15 mg / kg Q2W starting on Day 15) to achieve early target serum exposures of bemarituzumab in subjects. As described above, in a previous clinical study of bemarituzumab (FPA-144-004), an additional 7.5 mg / kg dose on Day 8 of Cycle 1 was added after the 15 mg / kg dose on Day 1 of Cycle 1 to help achieve these early target exposures (target trough coverage). Population PK modeling and simulations indicated that a 22 mg / kg dose on Day 1 of Cycle 1 achieved a similar C on Day 15 as a 15 mg / kg dose on Day 1 of Cycle 1 followed by an additional 7.5 mg / kg dose on Day 8 of Cycle 1. 谷 Therefore, the loading dose of 22 mg / kg on Day 1 not only helped achieve early target exposure but also improved subject convenience by eliminating the need for an additional 7.5 mg / kg Day 8 dose.

[0131] For Phase 2 of this study, the recommended dose of bemarituzumab will be determined based on the overall safety, tolerability, and PK evaluations of Phase 1 of the study.

[0132] End of study

[0133] If the individual subject has completed Figure 4 A patient is considered to have completed the study if he or she reaches the last visit shown in the activity schedule detailed in the study.

[0134] The study end date was defined as the date on which the last subject was assessed or received an intervention in the study for evaluation (i.e., the last visit of the last subject) across all study centers, including any additional components of the study (e.g., long-term follow-up, antibody testing), if applicable.

[0135] Study Group

[0136] The investigator will maintain a prescreening log and a screening log for all potential study candidates, including limited information about the potential candidates (e.g., screening date). Eligibility criteria will be evaluated during screening. Appropriate written informed consent must be obtained prior to any study-specific activities / procedures. Prospective approval for protocol deviations (also known as protocol waivers or exemptions) from recruitment and enrollment criteria will not be provided.

[0137] Inclusion criteria

[0138] Subjects were eligible for inclusion in the study only if all of the following criteria applied.

[0139] Subjects provided informed consent / assent before any study-specific activities / procedures began.

[0140] The age was ≥18 years (or the legal age of majority in the country, whichever is older) when signing the informed consent form (ICF).

[0141] Histologically or cytologically confirmed cancer of one of the following types is refractory or relapsed after at least 1 previous standard treatment regimen in the advanced / metastatic setting, as described below. If there is no standard of care therapy for the subject, or the subject cannot tolerate or refuses standard of care anticancer therapy, the subject may be allowed to participate in the study after discussion between the investigator and the Amgen medical monitor. Subjects who have not received all approved or standard cancer treatments must be informed that these alternatives to receiving bemarituzumab are available before agreeing to participate in the trial.

[0142] Head and neck squamous cell carcinoma: ≥ 1 line of therapy

[0143] Triple-negative breast cancer: ≥2 lines of therapy

[0144] Intrahepatic cholangiocarcinoma ≥ 1 line of therapy

[0145] Lung adenocarcinoma: at least platinum-based chemotherapy, checkpoint

[0146] Inhibitors and targeted therapies (ie, if molecular testing has identified a targetable mutation in EGFR, ALK, etc.)

[0147] Platinum-resistant epithelial ovarian cancer, including fallopian tube cancer

[0148] and primary peritoneal cancer, defined as progression during or within 6 months of a platinum-containing regimen: ≥1 line of therapy

[0149] Endometrial adenocarcinoma: ≥1 line of therapy

[0150] Cervical cancer: ≥1 line of therapy

[0151] Other solid tumors: ≥1 line of therapy

[0152] Unresectable locally advanced or metastatic (not amenable to curative therapy) disease

[0153] Tumors overexpress FGFR2b as determined by centrally performed immunohistochemistry (IHC) testing and have measurable disease according to RECIST v1.1

[0154] Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

[0155] Adequate hematologic and organ function, defined as follows:

[0156] Absolute neutrophil count ≥ 1.5 x 10 9 / L

[0157] Platelet count ≥100 x 10 9 / L

[0158] Hemoglobin ≥ 9 g / dL

[0159] AST and ALT <3x upper limit of normal [ULN] (or <5x ULN in case of liver involvement). Total bilirubin <1.5x ULN (or <2x ULN in case of liver involvement or Gilbert's disease).

[0160] Calculated or measured creatinine clearance (CrCl) ≥ 30 mL / min using the formula of Cockcroft and Gault ([140 – age] x weight [kg] / [72 x creatinine mg / dL]) (x 0.85 if female). Twenty-four-hour urine collection is not required but is permitted.

[0161] International normalized ratio (INR) or prothrombin time (PT) <1.5×ULN, except for subjects receiving anticoagulant therapy, who must have received a stable dose of anticoagulant therapy for 6 weeks prior to enrollment

[0162] Exclusion criteria

[0163] If any of the following criteria applied, the subject was excluded from the study.

[0164] Related diseases

[0165] Untreated or symptomatic central nervous system (CNS) metastases or leptomeningeal disease.

[0166] Subjects with asymptomatic CNS metastases are eligible if they have been clinically stable for at least 4 weeks and have not required intervention (including the use of corticosteroids).

[0167] Subjects with treated brain metastases are eligible if they meet the following criteria:

[0168] Complete definitive therapy at least 2 weeks before the first planned dose of study treatment (stereotactic radiosurgery at least 7 days before the first planned dose of study treatment)

[0169] At least 7 days before the first planned dose of study treatment: any CNS disease is clinically stable, the subject is off steroids for CNS disease (unless the reason for steroid use is unrelated to CNS disease), and the subject is off or on a stable dose of anti-epileptic medication

[0170] The other solid tumor cohort did not include CNS primaries, squamous non-small-cell lung cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma.

[0171] Other medical conditions

[0172] History of other malignancies within the past 2 years, except for the following:

[0173] Curative treatment of non-melanoma skin malignancies

[0174] Cervical cancer in situ

[0175] Curative treatment of uterine cancer stage I

[0176] Curatively treated ductal or lobular breast cancer in situ who have not received any systemic therapy

[0177] Localized prostate cancer treated with surgery that was intended to be curative and presumed to be curative

[0178] Impaired cardiac function or clinically significant heart disease, including: unstable angina within 6 months before the first dose of study treatment, acute myocardial infarction <6 months before the first dose of study treatment, New York Heart Association (NYHA) class II-IV congestive heart failure, uncontrolled hypertension (defined as mean systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg despite optimal treatment), uncontrolled arrhythmias requiring antiarrhythmic therapy other than beta blockers or digoxin, active coronary artery disease, or corrected QT interval (QTc) ≥470.

[0179] Active infection requiring systemic therapy or uncontrolled infection within 14 days prior to first dose of study treatment.

[0180] Known human immunodeficiency virus (HIV) infection with a CD4+ T cell (CD4+) count <350 cells / μL, hepatitis C infection (hepatitis C subjects who have achieved a sustained virologic response after antiviral therapy are allowed), or hepatitis B infection (subjects with hepatitis B surface antigen [SAg] or core antibodies who have achieved a sustained virologic response with antiviral therapy against hepatitis B are allowed).

[0181] History of systemic illness or ocular disorder requiring long-term use of ophthalmic steroids.

[0182] Any evidence of ongoing ophthalmologic abnormalities or symptoms that are acute (within 4 weeks) or actively progressing.

[0183] Unwilling to avoid contact lens use during study treatment and for at least 100 days after completion of treatment.

[0184] Recent (within 6 months) corneal surgery or laser ophthalmic treatment, or recent (within 6 months) history or evidence of corneal defects, corneal ulcers, keratitis, or keratoconus, or other known corneal abnormalities that may increase the risk of developing corneal ulcers.

[0185] Prior / concomitant therapy

[0186] Prior treatment with any investigational selective inhibitor of the FGF-FGFR pathway (unless approved standard of care for oncology indication).

[0187] Received any anticancer therapy or immunotherapy within 4 weeks before enrollment;

[0188] Palliative radiation therapy is allowed if it is completed more than 14 days before the first dose of study treatment

[0189] All treatment-related toxicities were required to resolve to ≤ Grade 1 before the first dose of study treatment, with the exception of alopecia or toxicity considered irreversible (defined as present and stable for >21 days) that was not otherwise described in the exclusion criteria

[0190] Major surgical procedure within 28 days prior to the first dose of study treatment.

[0191] Minor surgery requiring local / epidural anesthesia must be completed more than 72 hours prior to the first dose of study treatment. In all cases, subjects must be adequately recovered and stable prior to treatment administration.

[0192] Prior / concurrent clinical research experience

[0193] Currently receiving treatment in another investigational device or drug study, or less than 28 days after completing treatment in another investigational device or drug study (or studies). Participation in other investigational procedures concurrent with this study is excluded.

[0194] Other Exclusions

[0195] Female subjects of reproductive potential who do not wish to use protocol-specified contraception during treatment and for an additional 90 days after the last dose of bemarituzumab, see Appendix 5 (section 11.5).

[0196] Female subjects were breastfeeding or planned to breastfeed during the study period and up to 90 days after the last dose of bemarituzumab.

[0197] Female subjects planned to become pregnant during the study period up to 90 days after the last dose of bemarituzumab.

[0198] Female subjects of childbearing potential were assessed by a positive pregnancy test at screening using a high-sensitivity serum pregnancy test.

[0199] The subject has known sensitivities to any product to be administered during the dosing period.

[0200] To the knowledge of the subject and the investigator, the subject may not be able to complete all protocol-required study visits or procedures and / or comply with all required study procedures.

[0201] History or evidence of any other clinically significant disorder, condition, or disease (other than those outlined above) that, in the opinion of the Investigator or Amgen physician (if consulted), would pose a risk to the subject’s safety or interfere with study evaluations, procedures, or completion.

[0202] Subjects belonging to vulnerable groups (prisoners, institutionalized individuals, adult subjects under legal protection measures [judicial protection or guardianship measures], or other persons who may be considered vulnerable), unless otherwise specified (e.g., illiterate or visually impaired individuals).

[0203] Subject enrollment

[0204] The following items are required before subjects begin participating in any study-specific activities / procedures: written Institutional Review Board / Independent Ethics Committee (IRB / IEC) approval of the protocol from the study center, the informed consent form, and a copy of all other subject information and / or recruitment materials (if applicable).

[0205] The subject or the subject's legally authorized representative must personally sign and date the informed consent form approved by the IRB / IEC before commencing study-specific procedures.

[0206] Each subject who enters the study screening period (defined as when the subject signs the informed consent form) will receive a unique subject identification number before any study-related activities / procedures. The subject identification number will be assigned via interactive response technology (IRT). This number will be used to identify the subject throughout the clinical study and must be used in all study records related to that subject.

[0207] The subject identification number must remain constant throughout the clinical study; it may not be changed after initial assignment, including when subjects are rescreened.

[0208] When the Investigator determines that a subject meets all eligibility criteria, the subject is considered enrolled. The Investigator will record this decision and date in / on the subject's medical record and the subject's enrollment case report form (CRF).

[0209] Screening failure

[0210] Screening failures are defined as subjects who agree to participate in the main clinical study but are subsequently not enrolled in the study (subjects who do not express FGFR2b during the pre-screening period will not be counted as screening failures). A minimum set of screening failure information will be collected, including demographics, screening failure details, eligibility criteria, medical history, previous therapy, and any serious adverse events. Individuals who do not meet the criteria for participation in this study (screening failures) may be rescreened.

[0211] Bemarituzumab

[0212] Information regarding bemarituzumab in this study, including dosing and dosing instructions, is shown in Table 3 below.

[0213] Table 3

[0214]

[0215]

[0216] eCRF = electronic case report form; IV = intravenous; Q2W = every 2 weeks

[0217] Dose level determination

[0218] Two dose levels may be explored in Part 1: Dose Level 1 (22 mg / kg IV on Day 1 of Cycle 1, followed by 15 mg / kg IV Q2W starting on Day 15 thereafter) and Dose Level 1A (15 mg / kg IV Q2W plus 1 additional 7.5 mg / kg dose on Day 8 of Cycle 1). Part 1 of the study will begin with Dose Level 1 (22 mg / kg IV on Day 1 of Cycle 1, followed by 15 mg / kg IV Q2W starting on Day 15 thereafter). The study DLT evaluation period is 28 days. Once 3 to 6 subjects have completed the DLT period, a Dose Level Review Team (DLRT) meeting will be held.

[0219] In Part 1, the DLRT will use guidelines based on the mTPI-2 design. The mTPI-2 escalation / decrement guidelines for each dose cohort are derived with a target toxicity probability of 0.25 and an acceptable toxicity probability interval of (0.20, 0.30). If the estimated probability of a dose level exceeding the target DLT (i.e., eliminating the margin) is 95% or higher, the dose level will be considered unsafe and no additional subjects will be enrolled at that dose level. The specific guidelines are as follows:

[0220] Subjects in the first treatment group were treated at dose level 1

[0221] To assign doses to the next treatment group, the guidelines in Table 4 will be used.

[0222] · “Elimination” means eliminating current and higher doses from the trial to prevent treatment of any future subjects at those doses because they are too toxic.

[0223] When the dose is eliminated, decrement to dose level 1A. When the lowest dose is eliminated, stop the study for safety reasons.

[0224] When the dose is lower and the rules dictate dose escalation, treat new subjects at the higher dose.

[0225] If no action is triggered (ie, tapering or elimination), treat new subjects at the current dose.

[0226] If the current dose is the lowest dose and the rules indicate dose reduction, treat new subjects at the lowest dose unless the number of DLTs reaches the elimination boundary, at which point the trial is stopped for safety reasons.

[0227] If the current dose is the highest dose and the rule indicates dose escalation, treat the new patient at the highest dose.

[0228] The above steps were repeated until the maximum sample size of 18 was reached or the number of subjects treated at the current dose reached 9 and the decision according to Table 4 was to maintain the current dose.

[0229] Table 4. Dose escalation / decrease rules for the mTPI-2 design

[0230]

[0231] DLT = dose-limiting toxicity; mTPI = modified toxicity probability interval; NA = not applicable

[0232] The # of DLTs is the number of subjects with at least 1 DLT.

[0233] "NA" means the dose could not be eliminated before 3 subjects were treated.

[0234] When no action is triggered (ie, increment, decrement, or elimination), the next cohort of subjects is treated at the current dose.

[0235] Dose-limiting toxicity

[0236] Dose-limiting toxicity was defined as any of the following adverse events that the investigator considered to be at least possibly related to bemarituzumab during the DLT evaluation period (28 days):

[0237] Grade 4 neutropenia of any duration

[0238] Febrile neutropenia

[0239] Grade 4 thrombocytopenia

[0240] Grade 3 thrombocytopenia, > Grade 2 bleeding or lasting > 7 days

[0241] Grade 4 anemia

[0242] Grade 5 toxicity (e.g., death not due to disease progression)

[0243] Any grade 3 ophthalmic adverse event that does not resolve within 3 days

[0244] Any grade 4 ophthalmic adverse event

[0245] Any Level 4 laboratory value

[0246] Grade 4 vomiting or diarrhea

[0247] Grade 3 vomiting or Grade 3 diarrhea persists for more than 3 days despite best medical support

[0248] Grade 3 nausea persisting for 3 or more days despite best medical support

[0249] Grade 3 fatigue lasting 1 week or longer

[0250] Any subject who meets Hy's Law case criteria (i.e., severe drug-induced liver injury [DILI]) will be considered a DLT. A Hy's Law case is defined as an AST or ALT value ≥3x ULN and a serum total bilirubin (TBIL) level >2x ULN or INR>1.5, with no signs of cholestasis and no other clear alternative causes to explain the observed liver-related laboratory abnormalities (see section 11.7 for further explanation of Hy's Law cases and management of liver function).

[0251] Any other adverse events of grade 3 or higher, except for the following:

[0252] -DLT waived: Asymptomatic grade 3 amylase and / or lipase lasting <72 hours and no radiographic signs of pancreatitis

[0253] -DLT waiver: Asymptomatic Grade 3 electrolyte abnormalities lasting <72 hours, clinically uncomplicated, and resolving spontaneously or responding to medical intervention

[0254] -DLT waivers: other selected laboratory abnormalities that appear to be clinically irrelevant or not harmful to the subject (e.g., grade 3 lymphopenia, grade 3 hypoalbuminemia), and / or can be corrected with replacement or modification

[0255] -DLT exemption: transient (resolving to ≤ Grade 1 within 6 hours of onset) Grade 3 infusion-related adverse events

[0256] If subjects enrolled in dose-finding are not evaluable for DLT (e.g., subjects do not receive planned study treatment [100% of planned dose of bemarituzumab] or discontinue study treatment before the DLT evaluation period is completed for reasons other than experiencing a DLT), these subjects may be replaced. The replaced subject may continue on the study at the discretion of the investigator and after discussion with the Medical Monitor. Dosing will be stopped for the individual for any occurrence of a DLT or if the criteria are met.

[0257] Rules for dose modification, delay, suspension or restart, and permanent discontinuation of bemarituzumab

[0258] The dose of Bemmarituzumab may be withheld for Bemmarituzumab-related adverse events following the guidelines outlined in Tables 5.1, 5.2, and 5.3. The reason for dose delay of Bemmarituzumab will be recorded on each subject's CRF.

[0259] After Cycle 1, the bemaritumumab dose should be recalculated only if there is a >10% change in body weight based on Cycle 1 Day 1 body weight. If the dose is recalculated due to a >10% change in body weight relative to Cycle 1 Day 1, the body weight used for the recalculation should serve as the new baseline for dose recalculation for subsequent evaluations.

[0260] If the investigator is considering dose reductions or interruptions that are not within these guidelines, these will need to be discussed with the sponsor or designee.

[0261] Cycles may be delayed to manage toxicity. Any cycle delay of more than 21 days (regardless of the reason) should be discussed with the Medical Monitor prior to restarting.

[0262] Corneal events

[0263] Any subject who experiences a corneal event within 100 days after receiving the last dose of bemarituzumab (regardless of whether it is considered related to bemarituzumab) should be evaluated by an ophthalmologist. Any subject who reports eye pain or irritation or changes in vision should be evaluated by an ophthalmologist. Tables 5.1, 5.2, and 5.3 provide additional guidance.

[0264] Table 5.1. Guidelines for dose modifications of bemarituzumab for adverse events

[0265]

[0266]

[0267] Table 5.2 Guidelines for dose modification of bemarituzumab for adverse events

[0268]

[0269]

[0270] Table 5.3 Guidelines for dose modification of bemarituzumab for adverse events

[0271]

[0272]

[0273] CTCAE = Common Terminology Criteria for Adverse Events; IV = intravenous; N / A = not applicable; NSAID = nonsteroidal anti-inflammatory drug; aOcular adverse events other than corneal toxicity should follow dose modifications for all other bemarituzumab-related adverse events.

[0274] Previous treatment

[0275] All prior medications must be documented on the designated eCRF form. Prior therapies taken / used in the 3 months prior to enrollment will be collected.

[0276] For prior anticancer therapy for the cancer being studied, collect therapy name, setting, dose, unit, frequency, start date, stop date, best response, and reason for discontinuation traceable back to the initial diagnosis. For anticancer therapy that includes multiple separate components, information should be collected for each component. For all other prior therapies, collect therapy name, indication, dose, unit, frequency, route, start date, and stop date.

[0277] Concomitant therapy

[0278] Throughout the study, the investigator may prescribe any concomitant medication or treatment deemed necessary to provide adequate supportive care, with the exception of certain treatments.

[0279] To reduce the risk of corneal toxicity, prophylactic use of ocular lubricants and eyelid hygiene are recommended. Ocular lubricants (e.g., preservative-free artificial tears) should be self-applied at least 3 times daily throughout treatment and for 28 (+3) days after the last dose. They can be polyvinyl alcohol- or liquid polyol-based. If preservative-free is not feasible, formulations containing preservatives are permitted. Methylcellulose-based lubricants should not be used. Viscous lubricants that can cause haziness should be avoided.

[0280] Concomitant therapies will be collected from informed consent to the end of the SFU, with the exception of ophthalmic and anticancer therapies, which are collected through the LTFU. For concomitant therapies, including vaccines, collect the therapy name, indication, dose, unit, frequency, route, start date, and stop date. For subsequent anticancer therapies taken for the cancer being studied, collect the drug name, start date, and stop date.

[0281] Discontinuation of study treatment and subject discontinuation / withdrawal

[0282] Subjects have the right to withdraw from the study product and / or other protocol-required therapies, protocol procedures, or the entire study at any time and for any reason without affecting their future medical care by the physician or institution.

[0283] The Investigator and / or Sponsor may decide at any time prior to completion of the study to withdraw a subject from the investigational product, device, and / or other protocol-required therapy, protocol procedure, or the entire study.

[0284] Discontinuation of Study Treatment

[0285] The subject (or legally authorized representative) may refuse to continue receiving the investigational product and / or other protocol-required therapies and / or procedures at any time during the study but may continue to participate in the study. If this occurs, the investigator will discuss with the subject the appropriate process for discontinuing the investigational product or other protocol-required therapies and must discuss with the subject the continuation activity schedule (see Figure 4 ), including different follow-up options (e.g., in person, by phone / mail, through family / friends, correspondence / communication with other treating physicians, review of medical records) and data collection (including endpoints, adverse events), and this decision must be documented in the subject's medical record. Subjects who discontinue investigational product and / or other protocol-required therapies and / or procedures should not be automatically withdrawn from the study. It is necessary for subjects to continue participating in the study to ensure safety monitoring and / or collection of outcome data, when safe and feasible.

[0286] Reasons for premature withdrawal from one or more protocol-required evaluations of an investigational product or procedure may include any of the following:

[0287] ·Determined by the sponsor

[0288] Lost to follow-up

[0289] ·die

[0290] Adverse events

[0291] ·Subject requirements

[0292] · Determined not eligible

[0293] · Plan deviation

[0294] Disobedience

[0295] Disease progression

[0296] -Radiographic progression (RECIST v1.1)

[0297] -Clinical progression (investigator's assessment)

[0298] Need for alternative treatments

[0299] ·Pregnancy

[0300] Subject discontinuation / withdrawal from study

[0301] Withdrawal of research consent means that the subject does not wish to receive further protocol-required therapies or procedures and that the subject does not wish or cannot continue to participate in further research. The subject's data up to the time of withdrawal of consent will be included in the analysis of the study and, where permitted, publicly available data after the withdrawal of consent may be included. The investigator will discuss with the subject the appropriate procedures for withdrawal from the study and the subject's decision to withdraw must be documented in the subject's medical record.

[0302] If a subject withdraws from the study, he or she may request that any samples collected but not tested be destroyed.

[0303] Reasons for removing subjects from the study included: decision by the sponsor, withdrawal of study consent, death, and loss to follow-up.

[0304] Lost to follow-up

[0305] If a subject failed to return for multiple scheduled visits and the study center could not contact him or her, he or she was considered lost to follow-up.

[0306] If a subject fails to return to the clinic for a required study visit, the following actions must be taken:

[0307] The site must attempt to contact the subject and reschedule the missed visit as soon as possible, counsel the subject on the importance of maintaining the assigned visit schedule, and determine whether the subject wishes and / or is able to continue in the study.

[0308] In the event that a subject is considered lost to follow-up, the investigator or designee must make every effort to re-establish contact with the subject (three telephone calls where possible and, if necessary, a certified letter to the subject's last known mailing address, or local equivalent). These attempts at contact will be documented in the subject's medical record.

[0309] If the subject still could not be contacted, he / she would be considered withdrawn from the study, with the main reason being loss to follow-up.

[0310] For subjects lost to follow-up, investigators should search publicly available records, where permitted, to determine survival status. This ensures that the resulting data set is as comprehensive as possible.

[0311] Efficacy evaluation

[0312] Radiological imaging evaluation

[0313] The extent of disease will be evaluated by contrast-enhanced computed tomography (CT) / magnetic resonance imaging (MRI) according to RECIST v1.1. All radiological imaging will be performed according to institutional standards. To reduce the radiation exposure of the subject, low-dose CT should be used whenever possible.

[0314] Screening Scan:

[0315] The screening scan should be performed within 28 days prior to Cycle 1 Day 1 (the scan may be performed within 31 days) and include a clinical examination and appropriate imaging techniques (preferably a CT scan with appropriate slice thickness according to RECIST v1.1; MRI is acceptable). If there are multiple screening scans, the one closest to the enrollment date will be used as the baseline.

[0316] Radiological evaluation must include CT / MRI (with contrast) of the chest, abdomen, and pelvis, as well as evaluation of all other known disease sites. Tumor response assessments will be performed by the investigator according to RECIST v1.1 guidelines (section 11.9).

[0317] All subjects with brain metastases must undergo MRI of the brain. All brain scans for subjects with brain metastases are required to be MRI, unless MRI is contraindicated, in which case CT with contrast is acceptable. Brain imaging (MRI or CT) should be performed if signs or symptoms suggestive of CNS metastases are present.

[0318] Subsequent scans:

[0319] All subsequent scans should be performed in the same manner as the screening scan (e.g., same contrast agent, MRI field strength), ideally on the same scanner. If a change in imaging modality is necessary (e.g., unplanned assessment), consultation with the medical monitor is recommended.

[0320] During treatment and follow-up, the activity schedule (see Figure 4 ) at the treatment intervals specified in the study. Imaging may be performed more frequently if clinically necessary at the discretion of the treating physician. Radiologic imaging and tumor assessments will be performed until the initiation of new anticancer therapy, disease progression, death, withdrawal of consent, or end of the study, whichever occurs first.

[0321] Disease response determinations for clinical management and response assessment will be performed at the clinical research center according to RECIST v1.1. Responses will need to be confirmed by repeat scans 4 weeks after the first documented response. Scans for intrahepatic cholangiocarcinoma, cervical cancer, and head and neck cancer may be submitted to a central imaging core laboratory for archiving and, if necessary, response assessments (including RECIST v1.1) and / or exploratory analyses (e.g., volumetric and viable tumor measurements) may be performed.

[0322] Serum tumor markers

[0323] Serum tumor markers specific for each tumor type should be collected according to an activity schedule (see Figure 4 ). Tumor markers found elevated at baseline must normalize to confirm a radiographic CR. CA-125 should be collected within 2 weeks of screening for subjects with ovarian cancer. CA-125 response is defined as at least a 50% reduction in CA-125 in the pretreatment sample. CA-125 response must be confirmed and maintained for at least 28 days for subjects with ovarian cancer.

[0324] Safety Assessment

[0325] All safety assessments are scheduled to take place at Figure 4 Shown in

[0326] Vital signs

[0327] The following measurements must be taken: systolic / diastolic blood pressure, heart rate, respiratory rate, and temperature. The subject must be in a resting and calm state for at least 5 minutes prior to the blood pressure assessment. The position selected for the subject should be the same position used throughout the study and recorded on the Vital Signs CRF. The position selected for the subject for temperature should be the same position used throughout the study and recorded on the Vital Signs CRF. All measurements are recorded on the Vital Signs CRF.

[0328] Electrocardiogram (ECG)

[0329] The subject must be in a resting and calm state in the supine position for at least 5 minutes prior to the ECG assessment. If the subject is unable to be in the supine position, the subject should be in the most recumbent position possible. The ECG must include the following measurements: heart rate, QRS, QT, QTc, and PR interval. The PI or designated on-site physician will review all ECGs. Once signed, the original ECG tracing will be retained with the subject's source file.

[0330] Clinical laboratory evaluation

[0331] The Investigator is responsible for reviewing laboratory test results and recording any clinically relevant changes that occur during the study in the Event CRF. The Investigator must determine whether an abnormal value for an individual study subject represents a clinically significant change from the subject's baseline value. In general, abnormal laboratory findings that are not clinically significant (based on the Investigator's judgment) will not be recorded as adverse events. However, changes in laboratory values ​​that require treatment or adjustment of current therapy are considered adverse events. Where applicable, clinical sequelae (rather than laboratory abnormalities) will be recorded as adverse events.

[0332] All protocol-required laboratory assessments must be performed according to the activity plan ( Figure 4 )conduct.

[0333] Life Status

[0334] The vital status of all subjects must be obtained within the limits of local law. This includes subjects who may have discontinued study visits with or without consent withdrawal and should include searching public databases if necessary. If deceased, the date of death and reported cause of death should be obtained.

[0335] Eye examination

[0336] According to the activity schedule ( Figure 4 ) for ophthalmologic examinations. Investigators should report ophthalmic adverse events of any grade occurring up to 100 days after the last dose of bemarituzumab.

[0337] The ophthalmologic examination should include distance-corrected visual activity for each eye separately (where visual acuity is recorded as logMAR equivalents), slit-lamp examination of the anterior segment, pressure measurement (tonometry), and ocular surface staining (e.g., fluorescein). In addition, a dilated retinal examination or 3-field retinal photographs should be performed at screening and at each other ophthalmologic evaluation. In addition, optical coherence tomography (OCT) of the macula is specifically indicated for subjects with diagnosed or suspected retinal pigment epithelial (RPE) detachment. All assessments will be performed according to local practice.

[0338] Distance-corrected visual acuity will be assessed using the Snellen or Landolt C chart and must be recorded as logMAR equivalents. The same method should be used at screening and throughout the study. Other visual acuity charts may be used but must be approved in advance by the Medical Monitor.

[0339] According to the activity plan ( Figure 4 ) at the start of the SFU visit, regardless of dosing delay. Ophthalmological examinations may be repeated at any time as clinically indicated. After the SFU visit, if a subject has any persistent ophthalmological findings, they should continue to be evaluated until these findings resolve, consent is withdrawn, death, or loss to follow-up. Ophthalmologists should monitor for ocular adverse events until resolution.

[0340] The following actions will be implemented for ophthalmic adverse events:

[0341] Managed according to standards of care

[0342] Investigator guidance for dose modifications and interruptions is provided in (Table 5.1)

[0343] Subjects should be evaluated by an ophthalmologist if any clinically significant changes are noted from the previous examination or if the subject has any ocular signs or symptoms of grade 2 or higher.

[0344] Adverse Events

[0345] The adverse event grading scale used for this study will be the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

[0346] The investigator is responsible for ensuring that all adverse events observed by the investigator or reported by the subject that occur after the first dose of the investigational product until the end of the SFU are reported using the Event CRF.

[0347] Serious adverse events

[0348] The investigator is responsible for ensuring that all serious adverse events observed by the investigator or reported by the subject are reported using the Event CRF after signing of the informed consent until 28 (+3) days after the last day of the dosing interval of the study product.

[0349] All serious adverse events will be collected, recorded and reported to the Sponsor or designee within 24 hours after the Investigator becomes aware of the event. The Investigator will submit any updated serious adverse event data to the Sponsor within 24 hours of its availability.

[0350] Because the criteria of the CTCAE grading scale differ from the regulatory criteria for serious adverse events, if an adverse event corresponds to a grade 4 CTCAE toxicity grading scale criteria (e.g., laboratory abnormalities reported as grade 4 but not presenting a life-threatening condition), it will be left to the investigator’s discretion whether to also report these abnormalities as serious adverse events. For any adverse event that applies in this context, full documentation of the severity of the event must be recorded in the subject’s medical record.

[0351] If the investigator becomes aware of a serious adverse event suspected to be related to the IP or any fatal adverse event (regardless of causality) after the end of the protocol-required reporting period, these serious adverse events will be reported on the event CRF within 24 hours of the investigator becoming aware of the event.

[0352] For investigator-treated study subjects, there is no requirement to actively monitor study subjects after the study is completed. However, if the investigator becomes aware of serious adverse events suspected to be related to the study product after the protocol-required reporting period has ended, these serious adverse events will be reported on the event CRF within 24 hours of the investigator becoming aware of the event.

[0353] Because one of the study endpoints was overall survival, the investigators were responsible for ensuring that all fatal serious adverse events, regardless of causality, were collected and reported within 24 hours of becoming known.

[0354] Serious adverse events reported outside of the protocol-required reporting period will be captured in the safety database as clinical trial cases and handled accordingly based on their relationship to the investigational product.

[0355] If further safety-related data are needed to satisfy any regulatory reporting requirements for a reportable event, it may be necessary to collect additional information from the subject's records after the subject has left the study.

[0356] Follow-up of adverse events and serious adverse events

[0357] After the initial AE / SERV report, the investigator is required to actively follow up each subject at subsequent visits / contacts. All AEs and SERVs will be followed until resolved, stabilized, until the event has an alternative explanation, or the subject is lost to follow-up.

[0358] All new information on previously reported serious adverse events must be reported within 24 hours of becoming aware of the new information. If specifically requested, the investigator may need to provide additional follow-up information, such as discharge summaries, medical records, or medical record excerpts. The information provided regarding serious adverse events must be consistent with the information recorded on the event CRF.

[0359] Regulatory reporting requirements for serious adverse events

[0360] If a subject permanently withdraws from protocol-required therapy due to a serious adverse event, this information must be submitted to Amgen.

[0361] It is essential that investigators notify the sponsor of serious adverse events in a timely manner in order to fulfill their legal obligations and ethical responsibilities for the safety of subjects and the safety of study treatments in clinical studies.

[0362] Sponsors have a legal responsibility to inform local and other regulatory authorities about the safety of investigational treatments in clinical studies. Sponsors will comply with country-specific regulatory requirements related to reporting safety to regulatory authorities, IRBs / IECs, and investigators.

[0363] Individual safety reports must be prepared for suspected unexpected serious adverse reactions in accordance with local regulatory requirements and sponsor policy and forwarded to the investigator when necessary.

[0364] Investigators who receive individual safety reports describing serious adverse events or other specific safety information (e.g., summaries or tabulations of serious adverse events) from the sponsor will archive them with the Investigator's Brochure and will notify the IRB / IEC, as appropriate, in accordance with local requirements.

[0365] For studies that are blinded to treatment allocation, in order to comply with global serious adverse event reporting regulations, subjects with serious, unexpected and relevant adverse events may be unblinded to treatment allocation prior to submission to regulatory authorities. Pooled analyses may also be unblinded at the discretion of the safety assessment team. Investigators will be notified of relevant serious adverse event reports sent to regulatory authorities in accordance with local requirements.

[0366] Adverse Events of Special Interest

[0367] Adverse events selected to be referred to as bemarituzumab events of special interest are ocular adverse events of any grade or severity occurring up to 100 days after the last dose of bemarituzumab and should be collected as adverse events. Ocular adverse events (including corneal adverse events) should be graded using the ocular toxicity grading scale. Subjects should be assessed for possible bemarituzumab events of special interest prior to each dose.

[0368] Pregnancy and breastfeeding

[0369] Details of all pregnancies and / or breastfeeding in female subjects will be collected after the start of study treatment and within 90 days after the last dose of bemarituzumab.

[0370] Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, and ectopic pregnancy) were considered serious adverse events.

[0371] For females of childbearing potential, a high-sensitivity (serum) pregnancy test should be completed at Screening and within 72 hours of initiating the investigational product.

[0372] Women who have undergone bilateral tubal ligation / occlusion should undergo pregnancy testing as required by the protocol. (If a female subject or the partner of a male subject becomes pregnant, this must be reported on the pregnancy notification form).

[0373] Additional pregnancy testing should be performed on Day 1 of every other cycle during treatment and after discontinuation of protocol-required therapy on Day 28 (+3) (SFU), Day 56 (±3), and Day 75 (+3) from the last dose of bemarituzumab.

[0374] Additional on-treatment pregnancy testing may be performed at the investigator's discretion or as required according to local laws and regulations.

[0375] Pharmacokinetic evaluation

[0376] Whole blood samples will be collected for measurement of the activity schedule ( Figure 4 The sponsor will provide instructions for the collection and handling of biological specimens. The actual date and time (24-hour clock) of each specimen will be recorded.

[0377] Pharmacogenetic assessment

[0378] If the subject agrees to the optional pharmacogenetics part of this study, DNA analysis may be performed. These optional pharmacogenetic analyses focus on inherited gene variations to evaluate their possible relevance to the disease and / or responsiveness to the therapy used in this study. This optional assessment is separate from the genomic analysis of somatic mutations in tumor and circulating tumor DNA (ctDNA) samples included as part of the main study. The goals of the optional study include using genetic markers to help study cancer and / or identify subjects who may have a positive or negative response to the research product. No additional samples were collected in this part of the study. For subjects who agree to this / these analyses, DNA can be extracted.

[0379] Antibody testing procedures

[0380] According to the activity schedule ( Figure 4 ) to measure anti-bemarituzumab antibodies. Samples that test positive for binding antibodies can be further characterized.

[0381] Subjects who test positive for antibodies at the final scheduled antibody time point and have clinical sequelae that are considered possibly related to anti-bemarituzumab antibody response will also be asked to return for additional follow-up testing. This testing will be performed approximately every 3 months starting at the final scheduled antibody time point and continuing until: (1) antibodies are no longer detectable; or (2) the subject has been followed for at least 1 year (± 4 weeks) after administration of bemarituzumab. If safety-related concerns arise, more frequent testing or testing for longer periods of time may be requested.

[0382] Biomarkers

[0383] Biomarkers are objectively measured and evaluated indicators of normal biological processes, pathogenic processes, or pharmacological responses to therapeutic interventions.

[0384] Biomarker Assessment to Determine Eligibility

[0385] Archived tumor biopsies / excisions (except bone biopsies and cytology samples) formalin-fixed and paraffin-embedded (within 5 years or fresh biopsies if archived samples are not available) are required to pre-screen for FGFR2b overexpression status by IHC, and subjects must consent to tumor tissue analysis. If FGFR2b overexpression is confirmed, PD-L1 will also be tested on the remaining pre-screening tissue (if available) in head and neck squamous cell carcinoma, triple-negative breast cancer, lung adenocarcinoma, cervical cancer, and endometrial cancer.

[0386] Subjects will be selected for enrollment based on FGFR2b overexpression status, as determined by clinical trial assay (CTA) IHC assay in a central Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (Roche Tissue Diagnostics, Tucson, Arizona, US) that complies with United States (US) regulatory requirements. The timing of sample collection is as described in the activity schedule ( Figure 4 ). Collection of primary tumor and metastatic site specimens is permitted. If collection of fresh tissue samples is necessary, these should be obtained in accordance with local standards of care procedures, and these procedures are not expected to pose any additional significant risks to the health, safety, and well-being of the subjects.

[0387] The CTA used to select subjects was the VENTANA FGFR2b (FPR2 D) assay, an IHC test that determines FGFR2b overexpression status (positive, negative) in neoplastic tissue. Samples considered positive for FGFR2b overexpression status showed moderate (2+) to intense (3+) membrane staining in tumor cells.

[0388] Subjects deemed negative for FGFR2b overexpression status using IHC (no moderate or intense membrane staining in tumor cells) will not be eligible for enrollment. It is the responsibility of each investigator to obtain sufficient tumor specimens for analysis of FGFR2b status for enrollment. Blocks (if available) are preferred, but in lieu of blocks, unstained slides are recommended. The amount of tumor specimen submitted should be sufficient for IHC analysis; see the laboratory manual for details. Instructions for handling, labeling, and shipping of tumor slide or tumor block specimens are detailed in the laboratory manual that will be distributed with the specimen collection kit.

[0389] Once the tumor specimen is received, it will be analyzed as efficiently as possible and the results of FGFR2b overexpression status will be fed back to the investigator or designee. Figure 4 The remaining prescreening tissue, if available, is performed in the indications listed in the . This PD-L1 test is performed as a prescreening assessment for PD-L1 expression and overlap with FGFR2b, but the test results will not determine eligibility.

[0390] Biomarker Discovery

[0391] Samples will be collected to develop or address biomarker hypotheses related to bemarituzumab activity (e.g., to evaluate potential biomarkers that may be associated with treatment response). These samples may also be used to develop approaches that can better understand the disease.

[0392] If local regulations allow and the Ethics Committee (EC) / Institutional Review Board (IRB) agrees, the activity schedule ( Figure 4 ) for biomarker discovery. Blood samples will be collected and evaluated for potential associations of circulating tumor / cell-free DNA mutation profiles with clinical endpoints. Circulating tumor DNA plasma analysis will include mandatory paired analysis of subject blood samples to identify and select germline variants to help refine and identify tumor-specific mutations. Circulating tumor / cell-free DNA (ctDNA) assessments are used for analysis of somatic mutations. Germline mutation results will not be reported.

[0393] When tumor samples or optional biopsy samples are available, they may be used to examine protein expression, RNA and DNA gene expression, or somatic (tumor) mutation analysis, after providing additional consent. When tumor tissue is available, analysis for tumor-specific mutations or epigenetic changes (e.g., somatic mutations) may be performed. Exploratory genomic analysis of tumor tissue or biopsy may include paired sequencing analysis of a blood cell pellet sample from the subject to identify and select germline variants to help refine and confirm tumor-specific mutations. Germline mutation results will not be reported. None of these samples will be used for screening for genetic traits. Figure 4 Plasma samples as outlined in and biomarker analysis, such as proteomic analysis, can be performed.

[0394] Biomarker Development / Future Research

[0395] Biomarker development refers to the use of samples collected for biomarker discovery for future research after the study is completed.

[0396] In oncology, there is particular interest in the molecular changes underlying the carcinogenic process that can identify cancer subtypes, disease stage, assess tumor growth amounts, or predict disease progression, metastasis, and response to therapies called for by the investigational product or protocol.

[0397] If the subject provides consent, the activity schedule ( Figure 4 Any remaining samples collected at the time points specified in the FDA FDA Regulations (including samples collected for biomarker assessment) will be used for future research. No additional samples will be collected for biomarker development / future research.

[0398] Tests can be designed to identify subjects most likely to respond positively or negatively to an investigational product in order to study and further our understanding of cancer.

[0399] Statistical considerations

[0400] Statistical assumptions

[0401] No statistical hypotheses will be tested.

[0402] Sample size determination

[0403] In Part 1, if the true DLT rate in the 9 subjects treated at a dose level was 25%, the probability of observing at least 1 DLT was 92%. In Part 2, the Clopper-Pearson Exact 95% lower confidence limits corresponding to the observed ORRs of 11.1%, 16.7%, 22.2%, 27.8%, and 33.3% in 36 subjects were 3.1%, 6.4%, 10.1%, 14.2%, and 18.6%, respectively; the subjects assigned in Part 1 to the same dose level used in Part 2 would constitute a total of 36 subjects (see Table 6).

[0404] Table 6. 95% CI using Clopper-Pearson Exact method (N=36)

[0405]

[0406] CI = confidence interval; LCL = lower confidence limit; OR = objective response; UCL = upper confidence limit.

[0407] Note: "N" is the total sample size for a given tumor type cohort. "n" is the number of responses expected to be observed. Two-sided 95% confidence intervals were calculated using the Clopper--Pearson Exact method.

[0408] Analyze groups

[0409] The following groups are defined:

[0410]

[0411] Covariates

[0412] If applicable, the relationship between covariates and endpoints can be explored and specified in the statistical analysis plan (SAP).

[0413] Subgroup

[0414] If appropriate, subgroups can be explored and specified in the statistical analysis plan.

[0415] Statistical analysis

[0416] The statistical analysis plan will be developed and finalized before the database is locked. The following is a summary of the timing and methods of the planned statistical analysis. To maintain the integrity of the study, the final analysis will be performed and reported after the study is completed.

[0417] Plan Analysis

[0418] Part 1

[0419] In Part 1, the DLRT will be convened to review all available safety, tolerability, laboratory, and PK data during and after completion of Part 1 (28 days after enrollment of the last subject in Part 1). For dose-finding decisions, the DLRT will use guidelines based on the mTPI-2 design as described in Section 6.2.1.

[0420] Part 2

[0421] The DRT will review safety data after a specified number of subjects in the full analysis set (regardless of tumor type) have had an opportunity to be followed for 8 weeks. The specific number of subjects that will trigger a DRT review is specified in the first column of Table 7. To make this assessment, the DRT will use their clinical judgment in reviewing all relevant safety data and use the stopping guidelines in Table 7 based on a Bayesian posterior probability of >85% (i.e., the posterior probability of a Grade 4+ treatment-related adverse event rate exceeding 20% ​​using a beta (1,1) prior distribution).

[0422] Table 7. Safety Review Frequency and Stopping Boundaries for Grade 4+ Treatment-Related Adverse Events

[0423]

[0424] invalid

[0425] The DRT will monitor the non-binding ineffective interim analysis (two scans) that occurs after the first 12 and 24 subjects planned to be in the safety analysis set of a given tumor type cohort have the opportunity to complete the 16-week disease assessment. Enrollment will not be suspended for ineffective analysis. Stopping due to ineffectiveness will be based on a predicted probability of <20% after all 36 subjects are enrolled and have the opportunity to complete the 16-week disease assessment, that is, ORR will be>15%. A non-informative beta (1, 1) prior distribution will be used. If 0 of the 12 subjects or ≤1 of the 24 subjects have an OR (CR or PR), the cohort may be stopped due to ineffectiveness. Table 8 provides a range of 11 to 35 stopping guideline sample sizes to allow the DRT to evaluate multiple cohorts with different sample sizes in the same review. The operating characteristics of the stopping guidelines are described in Table 9.

[0426] Table 8. Stopping Guidelines

[0427] Number of evaluable subjects Number of ORs with invalid conclusions 11 to 22 0 23 to 34 1 or less 35 2 or less

[0428] OR = Total Response

[0429] Table 9. Stop Guide Operating Characteristics

[0430] Assumed ORR Probability of stopping due to ineffectiveness 5% 74.7% 10% 42.2% 15% 21.4% 30% 2.1% 40% 0.4%

[0431] ORR = objective response rate

[0432] Prior to the primary analysis of the entire study, additional interim analyses of selected efficacy and safety endpoints will be performed by tumor cohort once all subjects enrolled in that tumor cohort have had the opportunity to complete the 16-week disease assessment.

[0433] Preliminary and final analysis

[0434] The primary analysis will be conducted when all subjects in all tumor types have completed safety follow-up. All efficacy and safety endpoints will be analyzed in the primary analysis. The final analysis will be conducted when all subjects in all tumor types have completed the study. Event endpoint times will be updated with further follow-up for the final analysis.

[0435] Analytical methods

[0436] Parts 1 and 2 will be analyzed separately. For Part 1, safety analyses will be combined with tumor type; efficacy analyses will be presented by tumor type and only if sufficient sample size is available. For Part 2, efficacy analyses will be presented by tumor type; safety analyses will be presented by tumor type and overall. The primary analyses of efficacy and safety will be based on all enrolled subjects who received at least one dose of the investigational product. Continuous variables will be described using means, medians, quartiles, minimums, and maximums. Categorical data will be summarized using frequency counts and percentages. Confidence intervals (CIs) for proportions will be estimated using the exact method of Clopper-Pearson (Clopper and Pearson, 1934). The Kaplan-Meier (KM) method will be used to estimate medians and percentiles for time to event endpoints, with CIs calculated using the method of Brookmeyer and Crowley (Brookmeyer and Crowley, 1982). The Kaplan-Meier method will be used to estimate landmark time to event endpoints (eg, 1-year OS), with the Greenwood formula (Kalbfleisch and Prentice, 1980) used to estimate the standard error used in the CI calculations.

[0437] Efficacy analysis

[0438]

[0439] Security Analysis

[0440]

[0441] Adverse Events

[0442] Subject incidence rates for all treatment-emergent adverse events (e.g., ocular events) will be tabulated by system organ class and preferred term. Tabulations of Grade ≥3 events, Grade ≥4 events, fatal adverse events, serious adverse events, adverse events leading to study product discontinuation / withdrawal, and treatment-emergent adverse events of interest will also be provided.

[0443] Laboratory test results

[0444] Analyses of safety laboratory endpoints will include summary statistics over time. Shifts in safety laboratory value levels between baseline and worst study values ​​will be tabulated.

[0445] Vital signs

[0446] Analysis of vital signs will include summary statistics over time. Shifts in vital sign values ​​between baseline and worst study values ​​will be tabulated.

[0447] Physical Measurement

[0448] Analyses of physical measures will include summary statistics at baseline and potentially selected post-baseline time points.

[0449] Electrocardiogram

[0450] ECG measurements in this clinical study were performed according to the standard of care for routine safety monitoring and not to assess potential QTc effects. Because these evaluations may not necessarily be performed under the rigorous conditions expected for a meaningful evaluation of QTc data; no summary and statistical analysis of the ECG measurements were planned, and these data would not be expected to be useful for meta-analysis of data from other trials.

[0451] Antibody formation

[0452] The incidence and percentage of subjects who developed anti-bemarituzumab antibodies at any time will be tabulated.

[0453] Exposure to investigational products

[0454] Descriptive statistics will be used to summarize the number of days of study product use, total dose of study product, and dose intensity.

[0455] Exposure to concomitant medications

[0456] The number and proportion of subjects receiving the treatment of interest will be summarized by preferred terms coded by the World Health Organization Drug Dictionary.

[0457] Other analyses

[0458] The pharmacokinetic parameters of bemarituzumab will be determined, including but not limited to AUC, Cmax and Ctrough. The pharmacokinetic data collected from this study will be combined with the PK data collected from other bemarituzumab studies for population PK analysis. Additional analyses will be performed to evaluate the relationship between bemarituzumab exposure and selected safety or efficacy or any relevant biomarker endpoints (if data are available). The details and results of these exploratory analyses will be described in a separate report.

[0459] Example 3: Treatment of solid tumors with bemarituzumab - dose level 1

[0460] Separate cohorts of patients with pathologically confirmed or FGFR2b-overexpressing solid tumors were treated with bemarituzumab. Cohorts were organized according to tumor type as follows:

[0461] 1. Head and neck squamous cell carcinoma

[0462] 2. Triple negative breast cancer (ER-, PR-, HER2 / neu-)

[0463] 3. Intrahepatic bile duct carcinoma

[0464] 4. Lung adenocarcinoma

[0465] 5. Ovarian epithelial cancer, including fallopian tube cancer and primary peritoneal cancer

[0466] 6. Endometrial adenocarcinoma

[0467] 7. Cervical cancer

[0468] 8. Other solid tumors

[0469] Each cohort was treated with the following two-weekly (Q2W) regimen: a first administration of bemarituzumab at a dose of 22 mg / kg, followed by subsequent administrations of bemarituzumab at a dose of 15 mg / kg two weeks after the first administration and Q2W thereafter.

[0470] Bemarituzumab monotherapy was effective in treating solid tumors in these patients, as measured by objective response (defined as complete response (CR) + partial response (PR) as determined according to Response Evaluation Criteria in Solid Tumors [RECIST v1.1]).

[0471] Example 4: Treatment of solid tumors with bemarituzumab - dose level 2

[0472] Separate cohorts of patients with pathologically confirmed or FGFR2b-overexpressing solid tumors were treated with bemarituzumab. Cohorts were organized according to tumor type as follows:

[0473] 1. Head and neck squamous cell carcinoma

[0474] 2. Triple negative breast cancer (ER-, PR-, HER2 / neu-)

[0475] 3. Intrahepatic bile duct carcinoma

[0476] 4. Lung adenocarcinoma

[0477] 5. Ovarian epithelial cancer, including fallopian tube cancer and primary peritoneal cancer

[0478] 6. Endometrial adenocarcinoma

[0479] 7. Cervical cancer

[0480] 8. Other solid tumors

[0481] Each cohort was treated with the following biweekly (Q2W) regimen: anti-FGFR2b antibody was administered at a dose of 15 mg / kg, and one week after the first administration of anti-FGFR2b antibody, a single subsequent administration of anti-FGFR2b antibody was administered at a dose of 7.5 mg / kg.

[0482] Bemarituzumab monotherapy was effective in treating solid tumors in these patients, as measured by objective response (defined as complete response (CR) + partial response (PR) as determined according to Response Evaluation Criteria in Solid Tumors [RECIST v1.1]).

[0483] Example 5: Treatment of solid tumors with bemarituzumab - dose level 1

[0484] Separate cohorts of patients with pathologically confirmed or FGFR2b-overexpressing solid tumors were treated with bemarituzumab. Cohorts were organized according to tumor type as follows:

[0485] 1. Head and neck squamous cell carcinoma

[0486] 2. Triple negative breast cancer (ER-, PR-, HER2 / neu-)

[0487] 3. Intrahepatic bile duct carcinoma

[0488] 4. Lung adenocarcinoma

[0489] 5. Ovarian epithelial cancer, including fallopian tube cancer and primary peritoneal cancer

[0490] 6. Endometrial adenocarcinoma

[0491] 7. Cervical cancer

[0492] 8. Other solid tumors

[0493] Each cohort was treated with the following two-weekly (Q2W) regimen: a first administration of bemarituzumab at a dose of 22 mg / kg, followed by subsequent administrations of bemarituzumab at a dose of 15 mg / kg two weeks after the first administration and Q2W thereafter.

[0494] Bemarituzumab monotherapy is effective in treating solid tumors in these patients as measured by progression-free survival and / or overall survival.

[0495] Example 6: Treatment of solid tumors with bemarituzumab - dose level 2

[0496] Separate cohorts of patients with pathologically confirmed or FGFR2b-overexpressing solid tumors were treated with bemarituzumab. Cohorts were organized according to tumor type as follows:

[0497] 1. Head and neck squamous cell carcinoma

[0498] 2. Triple negative breast cancer (ER-, PR-, HER2 / neu-)

[0499] 3. Intrahepatic bile duct carcinoma

[0500] 4. Lung adenocarcinoma

[0501] 5. Ovarian epithelial cancer, including fallopian tube cancer and primary peritoneal cancer

[0502] 6. Endometrial adenocarcinoma

[0503] 7. Cervical cancer

[0504] 8. Other solid tumors

[0505] Each cohort was treated with the following biweekly (Q2W) regimen: anti-FGFR2b antibody was administered at a dose of 15 mg / kg, and one week after the first administration of anti-FGFR2b antibody, a single subsequent administration of anti-FGFR2b antibody was administered at a dose of 7.5 mg / kg.

[0506] Bemarituzumab monotherapy is effective in treating solid tumors in these patients as measured by progression-free survival and / or overall survival.

[0507] Example 7

[0508] The prevalence of FGFR2b overexpression was investigated in the procurement tissues of 10 tumor indications selected based on TCGA data and literature in order to update the tumor cohorts in this study (Table 10). Based on these data, tumor indications with an expected prescreening prevalence of 10% or higher (including those with a 95% confidence interval including 10%) were recruited as defined tumor cohorts. Of note, iCCA showed a prevalence of 1% (95% CI 0%-3%), but due to limitations associated with the rarity of the tumor type, most specimens were obtained from research centers in one country. Specimens from other tumor types were sourced from multiple countries to ensure geographic diversity. Therefore, the iCCA prevalence data from this study may not represent the broader prevalence of FGFR2b, as supported by published literature and early results from this study. Published literature suggests that FGFR2b is expressed (IHC staining ≥1) in approximately 31% (19 / 62 cases) of iCCAs (Junior et al., 2022). At the start of this study, four iCCA samples were received for pre-screening and 2 / 4 (50%) tested positive for any 2+3+FGFR2b level.

[0509] Table 10: Prevalence of FGFR2b overexpression in solid tumors (excluding gastric and squamous NSCLC)

[0510]

[0511]

[0512] a FGFR2b IHC was performed using the VENTANA FGFR2b (FPR2-D) robust prototype assay on procured stage III / IV FFPE tissue blocks from surgical resection or biopsy, and any 2+ / 3+ staining was considered FGFR2b overexpression.

[0513] b The geographic diversity of these procured iCCA tissues was limited. Most samples were obtained from research centers in a single country.

[0514] c Data from iCCA subjects. Sample size was very small.

[0515] In addition to gastric cancer and squamous non-small cell lung cancer (which are being studied in other bemarituzumab clinical trials), data on FGFR2b expression by immunohistochemistry (IHC) showed overexpression (defined as subjects with FGFR2b 2+ / 3+ membrane staining in tumor cells) in ovarian cancer (19%, 95% CI 14%-24%), endometrial cancer (23%, 95% CI 17%-29%), head and neck squamous cell carcinoma (22%, 95% CI 15%-29%), cervical cancer (10%, 95% CI 4%-16%), triple-negative breast cancer (8%, 95% CI 4%-13%), lung adenocarcinoma (6%, 95% CI 1%-11%), and intrahepatic cholangiocarcinoma (iCCA, 1%, 95% CI 0%-3%) (Table 10).

[0516] Example 8: Results of a Phase 1b basket study evaluating the safety, tolerability, pharmacokinetics, and efficacy of bemarituzumab monotherapy in solid tumors overexpressing FGFR2B

[0517] According to the scheme described in Example 2, if the patient's tumor sample shows any moderate (2+) to strong (3+) membrane staining, it is determined by immunohistochemistry (IHC) that they overexpress FGFR2b. According to the scheme described in Example 2 (Part 1, Phase 1b), the anti-FGFR2b antibody bemarituzumab is intravenously administered to patients with solid tumor types that overexpress FGFR2b. Patients were administered with 22mg / kg bemarituzumab on the 1st day of the 1st cycle ("C1 / D1"), followed by 15mg / kg bemarituzumab Q2W. The tumor types of these patients include pancreatic duct, colorectal, ovarian, head and neck (N=1) (pharmacokinetic data available for N=5 / 6 patients). Bemarituzumab serum concentrations were measured at pre-specified time points on days 0, 1 (intensive PK sampling), 2, 4, 8, 15, 21 and 43. The preliminary PK summary of bemarituzumab is shown in Table 11. After cycle 1, the geometric mean bemarituzumab C 最大 was 577 μg / mL, and C 谷 The concentration is 96.5μg / mL.

[0518] Table 11. Observed exposure to bemarituzumab (geometric mean: C 最大 and C 谷 ), based on data from a basket study Available preliminary PK data for 20210104 (data cutoff December 12, 2022)

[0519]

[0520] These data demonstrate that the pharmacokinetics of bemarituzumab are consistent with clinical models for the gastric cancer indication for dosing and scheduling, and that systemic bemarituzumab concentrations exceed the minimum predicted effective exposure threshold derived from nonclinical data (60 μg / mL).

[0521] Based on the known safety profile of bemarituzumab, there were no new safety findings in the patients.

[0522] References

[0523] Each of the following references is incorporated herein by reference in its entirety.

[0524] 2020-2021Basic and Clinical Science Course TM (BCSC); Section 3-ClinicalOptics.Ophthalmology.https: / / www.aao.org / bcscsnippetdetail.aspx? id=3550b1ca-1740-4e7f-8712-70905c99eb26.30June 2020.

[0525] Ahn S, Lee J, Hong M, et al. FGFR2 in gastric cancer: proteinoverexpression predicts gene amplification and high H-index predicts poorsurvival. Mod Pathol. 2016; 29(9):1095-1103.

[0526] Andre F, Ranson M, Dean E, et al. Abstract LB-145: Results of a Phase IStudy of AZD4547, an Inhibitor of Fibroblast Growth Factor Receptor (FGFR), in Patients with Advanced Solid Tumors. AACR 104th Annual Meeting 2013, Washington, DC, American Association of Cancer Research.

[0527] US Prescribing Information,2020.https: / / www.janssenlabels.com / package-insert / product-monograph / prescribing-information / BALVERSA-pi.pdf

[0528] Bemarituzumab Investigator’s Brochure.Thousand Oaks,CA.Amgen Inc.

[0529] Brands RC,Knierim LM,De Donno F,et al.Targeting VEGFR and FGFR inhead and neck squamous cell carcinoma in vitro.Oncology Reports.2017;38:1877-1885.

[0530] Brookmeyer R and Crowley J.A Confidence Interval for the MedianSurvival Time.Biometrics.1982;2984;38:29-41.

[0531] Brown AP,Courtney CL,King LM,et al.Cartilage Dysplasia and TissueMineralization in the Rat Following Administration of a FGF Receptor TyrosineKinase Inhibitor.Toxicologic Pathology.2005;33:449-455.

[0532] Catenacci,DVT;Rasco D;Lee J,et al.Phase I Escalation and ExpansionStudy of Bemarituzumab(FPA144)in Patients with Advanced Solid Tumors andFGFR2b Selected Gastroesophageal Adenocarcinoma.J Clin Oncol.2020;82(21):2418-2426.

[0533] Catenacci DVT,Kang Y-K,Saeed A,et al.FIGHT:Arandomized,double-blind,placebo-controlled,phase II study of bemarituzumab(bema)combined withmodified FOLFOX6 in 1L FGFR2b+advanced gastric / gastroesophageal junctionadenocarcinoma(GC)[Abstract].2021.J Clin Onc.2021;39(no 15_supp):4010.

[0534] Churi CR,Shroff R,Wang Y.Mutation Profiling in Cholangiocarcinoma:Prognostic and Therapeutic Implications.Plos One.2014;9(12):e115383.

[0535] The Common Terminology Criteria for Adverse Events,version 5.0:http: / / ctep.cancer.gov / protocolDevelopment / electronic_applications / ctc.htm

[0536] Clopper CJ and Pearson ES.The Use of Confidence or Fiducial LimitsIllustrated in the Case of the Binomial.Biometrika.1934;26:404-413.

[0537] Dienstmann R,Bahleda R,Barbara A,et al.First in human study of JNJ-42756493,a potent pan fibroblast growth factor receptor(FGFR)inhibitor inpatients with advanced solid tumors.AACR 105th Annual Meeting 2014,San Diego,CA.

[0538] Dutt A,Salvesen HB,Chen T-H,et al.Drug-sensitive FGFR2 mutations inendometrial carcinoma.Proc Natl Acad Sci U S A.2008;105(25):8713-8717.

[0539] Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluationcriteria in solid tumours:revised RECIST guideline(version 1.1).Eur JCancer.2009;45(2):228-247.

[0540] Gatius S,Velasco A,Azueta A,et al.FGFR2 alterations in endometrialcarcinoma.Modern Pathology.2011;24:1500-1510.

[0541] Gemo A,Deshpande A,Palencia S,et al.FPA144:ATherapeutic Antibody forTreating Patients with Gastric Cancers Bearing FGFR2 Gene Amplification.AACR105th Annual Meeting 2014,San Diego California.

[0542] Han X,Xiao Z,and Quarles LD.Membrane and integrative nuclearfibroblastic growth factor receptor(FGFR)regulation of FGF-23.J BiolChem.2021;290(16):10447-10459.

[0543] International Committee of Medical Journal Editors,UniformRequirements for Manuscripts Submitted to Biomedical Journals:Writing andEditing for Biomedical Publication.2013.http: / / www.icmje.org /

[0544] Kang X,Lin Z,Xu M,et al.Deciphering role of FGFR signalling pathwayin pancreatic cancer.Cell Proliferation.2019;52:e12605.

[0545] Kato H,Arao T,Matsumoto K,et al.Gene amplification of EGFR,HER2,FGFR2and MET in esophageal squamous cell carcinoma.In J Oncol.2013;42:1152-1158.

[0546] Katoh and Katoh.FGF signaling network in the gastrointestinal tract(review).Int J Oncol.2006;29(1):163-168.

[0547] Kalbfleisch JD and Prentice,RL.The Statistical Analysis of FailureTime Data,New York:John Wiley&Sons(1980)

[0548] Li P,Huang T,Zou Q,et al.FGFR2 Promotes Expression of PD-L1 inColorectal cancer via the JAK / STAT3 Signaling Pathway.J Immunol.2019;202:3065-3075.

[0549] Oken MM,Creech RH,Tormey DC,et al.Toxicity and response criteria ofthe Eastern Cooperative Oncology Group.Am J Clin Oncol.1982;5(6):649-655.

[0550] US Prescribing Information,2021.https: / / www.pemazyre.com / pdf / prescribing-information.pdf

[0551] Reintjes N,Li Y,Becker A,et al.Activating Somatic FGFR2 Mutations inBreast Cancer.Plos One.2013;8(3):e60264.

[0552] Sequist LV,Cassier P,Varga A,et al.Phase I Study of BGJ398,aSelective Pan-FGFR Inhibitor in Genetically Preselected Advanced SolidTumors.AACR 2014 Annual Meeting,San Diego,CA.

[0553] Shinkawa T,Nakamura K,Yamane N,et al.The Absence of Fucose but Notthe Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity.J Biol Chem.2003;278(5):3466-3473.

[0554] Sun Y,Cheng Y,Zhang Y,et al.MicroRNA-889-3p targets FGFR2 to inhibitcervical cancer cell viability and invasion.Experimental and TherapeuticMedicine.2019;18:1440-1448.

[0555] Tokunaga R,Imamura Y,Nakamura K,et al.Fibroblast growth factorreceptor 2expression,but not its genetic amplification,is associated withtumor growth and worse survival in esophagogastric junctionadenocarcinoma.Oncotarget.2016;7(15):19748-19761.

[0556] Tyulyandina A,Demidova I,Gikalo M,et al.Role of FGFR2 amplificationin prognosis of patients with ovarian cancer.2018;29(8):viii354-viii355.

[0557] Wu YM, Su F, Kalyana-Sundaram, et al. Identification of Targetable FGFRGene Fusions in Diverse Cancers. Cancer Discovery. 2013; 3(6): 636-647.

[0558] Xiang H, Chan AH, Ahene A, et al. Preclinical characterization of bemarituzumab, an FGFR2b antibody for the treatment of cancer. MAbs. 2021; 13(1):1981202.

[0559] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

[0560] Unless otherwise indicated herein or clearly contradicted by the context, the use of the terms "one" and "a kind of" and "the" and "at least one" and similar indicators in the context of describing the present invention (particularly in the context of the following claims) will be interpreted as covering both the singular and the plural. The use of the term "at least one" followed by a list of one or more items (e.g., "at least one of A and B") should be interpreted as indicating one item selected from the listed items (A or B) or any combination of two or more listed items (A and B), unless otherwise indicated herein or clearly contradicted by the context. Unless otherwise indicated, the terms "comprising", "having", "including" and "containing" will be considered open terms (i.e., meaning "including but not limited to"). Unless otherwise indicated herein, the statements of the range of values ​​herein are intended to be used only as a shorthand method of referring to each independent value within the range individually, and each independent value is incorporated into the specification as if the value were individually stated herein. Unless otherwise indicated herein or clearly contradicted by the context, all methods described herein can be performed in any suitable order. The use of any and all examples or exemplary language (e.g., "such as") provided herein is intended only to better describe the invention and does not impose limitations on the scope of the invention unless otherwise required. No language in this specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[0561] Preferred embodiments of the present invention are described herein, including the best mode known to the inventor for implementing the present invention. After reading the above description, the changes of those preferred embodiments are obvious to those of ordinary skill in the art. The inventor expects that a skilled person will appropriately adopt such changes, and the inventor intends to practice the present invention in a manner other than that clearly described herein. Therefore, the present invention includes all modifications and equivalents of the subject matter listed in the appended claims as permitted by applicable law. In addition, unless otherwise indicated herein or clearly contradictory to the context, the present invention covers any combination of the above-mentioned elements in all possible variations thereof.

Claims

1. A method of treating a solid tumor in a subject, the method comprising administering to the subject an anti-FGFR2b antibody monotherapy, the monotherapy comprising: (a) the following two-week (Q2W) regimen: a first administration of the anti-FGFR2b antibody at a dose of greater than 20 mg / kg to no more than 30 mg / kg, followed by subsequent administrations of the anti-FGFR2b antibody at a dose of 12-20 mg / kg each two weeks after the first administration and Q2W thereafter, wherein the doses of these subsequent administrations are lower than the first administration; or (b) the following two-week (Q2W) regimen: the anti-FGFR2b antibody at a dose of greater than 10 mg / kg to no more than 20 mg / kg, and one week after the first administration of the anti-FGFR2b antibody, a single subsequent administration of the anti-FGFR2b antibody at a dose of 5-10 mg / kg.

2. The method of claim 1, wherein the solid tumor is selected from the group consisting of squamous cell carcinoma, ER-PR-HER2 / neu- ("triple negative") breast cancer, pancreatic ductal adenocarcinoma, intrahepatic bile duct carcinoma, colorectal adenocarcinoma, and gynecological malignancies.

3. The method of claim 1, wherein the solid tumor is selected from the group consisting of squamous carcinoma (such as head and neck squamous cell carcinoma), ER-PR-HER2 / neu- ("triple negative") breast cancer, intrahepatic bile duct carcinoma, gynecological malignancies, and lung adenocarcinoma.

4. The method of any one of claims 1-3, wherein the anti-FGFR2b antibody monotherapy is administered as a second-line or higher-line therapy, such as a third-line or higher-line therapy, for the solid tumor.

5. The method of any one of claims 2-4, wherein the squamous carcinoma is head and neck cancer or squamous esophageal cancer.

6. The method of any one of claims 2-4, wherein the squamous carcinoma is head and neck squamous cell carcinoma.

7. The method of any one of claims 2-6, wherein the gynecological malignancy is selected from the group consisting of ovarian epithelial cancer (such as fallopian tube cancer or primary peritoneal cancer), endometrial cancer, and cervical cancer.

8. The method of any one of claims 2-7, wherein the squamous carcinoma is post-platinum-based chemotherapy and / or post-PD-1 inhibitor.

9. The method of any one of claims 2-8, wherein the triple-negative breast cancer is post-chemotherapy, post-PARPi (if BRCA mutated), post-PD-1 inhibitor therapy and / or post-antitrop-2 therapy.

10. The method according to any one of claims 2 to 9, Pancreatic ductal adenocarcinoma after platinum-based chemotherapy wherein the intrahepatic cholangiocarcinoma is post-platinum-based chemotherapy and, if eligible for targeted therapy, the intrahepatic cholangiocarcinoma is post-targeted therapy, and / or wherein the colorectal adenocarcinoma is post-bevacizumab therapy, post-oxaliplatin-based chemotherapy, post-irinotecan-based chemotherapy, and / or post-additional prior therapy based on RAS, BRAF, and dMMR / MSI-H status.

11. The method of any one of claims 2-4 or 7, wherein the gynecological malignancy is post-platinum-based chemotherapy and / or is platinum chemotherapy-resistant.

12. The method of any one of claims 2-11, wherein cells of the solid tumor overexpress FGFR2b mRNA or protein, or contain FGFR2 gene amplification.

13. The method of any one of claims 1-12, wherein the solid tumor overexpresses FGFR2b as determined by immunohistochemistry (IHC).

14. The method of claim 13, wherein cells of the solid tumor are positive for FGFR2b as determined by IHC, optionally wherein at least 5%, 10% or 20% of the cells are positive for FGFR2b.

15. The method of claim 13, wherein cells of the solid tumor exhibit 2+ and / or 3+ FGFR2b staining as determined by IHC, optionally wherein at least 5%, 10% or 20% of the cells exhibit said FGFR2b staining.

16. The method of any one of claims 1-15, wherein (a) the first administration of the anti-FGFR2b antibody is at a dose greater than 20 mg / kg to no more than 25 mg / kg, followed by subsequent administrations of the anti-FGFR2b antibody at a dose of 12-17 mg / kg each two weeks after the first administration and Q2W thereafter.

17. The method of any one of claims 1-16, wherein (a) the first administration of the anti-FGFR2b antibody is at a dose of 22-25 mg / kg, followed by subsequent administrations of the anti-FGFR2b antibody two weeks after the first administration and Q2W thereafter each at a dose of 12-17 mg / kg.

18. The method of any one of claims 1-17, wherein (a) the first administration of the anti-FGFR2b antibody is at a dose of about 22 mg / kg, followed by subsequent administrations of the anti-FGFR2b antibody two weeks after the first administration and Q2W thereafter each at a dose of about 15 mg / kg.

19. The method of any one of claims 1-15, wherein (b) the dose of the Q2W regimen of the anti-FGFR2b antibody is 12-17 mg / kg, and the dose of the subsequent single administration of the anti-FGFR2b antibody one week after the first administration of the anti-FGFR2b antibody is 7-8 mg / kg.

20. The method of any one of claims 1-15, wherein (b) the dose of the Q2W regimen of the anti-FGFR2b antibody is about 15 mg / kg and the dose of the subsequent single administration of the anti-FGFR2b antibody one week after the first administration of the anti-FGFR2b antibody is about 7.5 mg / kg.

21. The method of any one of claims 1-20, wherein the anti-FGFR2b antibody is administered intravenously.

22. The method of any one of claims 1-21, wherein the anti-FGFR2b antibody comprises: a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1 of SEQ ID NO: 6, a HCDR2 of SEQ ID NO: 7, and a HCDR3 of SEQ ID NO: 8; and A light chain variable region comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO:9, LCDR2 of SEQ ID NO:10, and LCDR3 of SEQ ID NO:

11.

23. The method of any one of claims 1-22, wherein the anti-FGFR2b antibody is afucosylated.

24. The method of any one of claims 20-23, wherein the heavy chain variable region comprises an amino acid sequence at least 95% identical to SEQ ID NO:4, and wherein the light chain variable region comprises an amino acid sequence at least 95% identical to SEQ ID NO:

5.

25. The method of any one of claims 20-23, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:4, and wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:

5.

26. The method of any one of claims 20-25, wherein the anti-FGFR2b antibody comprises a heavy chain of SEQ ID NO: 1 and a light chain of SEQ ID NO: 2, and wherein the anti-FGFR2b antibody lacks fucose at Asn297 (EU numbering).

27. The method of any one of claims 1-26, wherein the anti-FGFR2b antibody is bemarituzumab.

28. The method of claim 27, wherein the bemarituzumab is administered intravenously, wherein (a) the dose of the first administration is greater than 20 mg / kg to no more than 25 mg / kg, followed by subsequent administrations of the bemarituzumab two weeks after the first administration and Q2W thereafter each at a dose of 12-17 mg / kg.

29. The method of claim 27, wherein the bemarituzumab is administered intravenously, wherein (a) the first administration is at a dose of 22-25 mg / kg, followed by subsequent administrations of the bemarituzumab two weeks after the first administration and Q2W thereafter each at a dose of 12-17 mg / kg.

30. The method of claim 27, wherein the bemarituzumab is administered intravenously, wherein (a) the first administration is at a dose of about 22 mg / kg, followed by subsequent administrations of the bemarituzumab two weeks after the first administration and Q2W thereafter each at a dose of about 15 mg / kg.

31. The method of claim 27, wherein the bamarituzumab is administered intravenously, wherein (b) the dose of the Q2W regimen of the bamarituzumab is 12-17 mg / kg, and the dose of the subsequent single administration of the bamarituzumab one week after the first administration of the bamarituzumab is 7-8 mg / kg.

32. The method of claim 27, wherein the bamarituzumab is administered intravenously, wherein (b) the dose of the Q2W regimen of the bamarituzumab is about 15 mg / kg, and the dose of the subsequent single administration of the bamarituzumab one week after the first administration of the bamarituzumab is about 7.5 mg / kg.

33. The method of any of the preceding claims, wherein the solid tumor is PD-L1 positive as determined by IHC staining.